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Abstract 
 
One of the greatest challenges in the f ield of biomedical technology, is to f ind 
new t echniques to det ect, di agnose and interpret c omplex hu man di sease 
conditions. The need  t o anal yze or  m easure endog enous biological m arkers 
related t o di fferent di seases has stimulated t he co ntinuous search f or m ore 
effective and se nsitive analytical methods which will eventually also contribute 
to better therapy. 
The development of reliable bio-analytical methods is of utmost importance for 
the total care of a pat ient and i f such a method can be developed to aid in the 
diagnosis of esp ecially psychiatric conditions (e.g. s tress-related di sorders, 
depression etc.) the benefits will be incalculable. 
In the central nervous system catecholamines are naturally occurring chemicals 
called neur otransmitters and i n t he blood t hey are ho rmones secreted by the 
adrenal medullae. They are very important for proper brain and b ody function 
because they relay signals between nerve cells. Norepinephrine is one of  the 
main catecholamines and 3-methoxy-4-hydroxyphenylglycol (MHPG) is one of  
its metabolites. Several studies from l iterature have confirmed that analysis of 
MHPG in saliva may be a biological marker for detecting changes in the central 
and peripheral catecholamine metabolism while also reflecting some aspects of 
mental functioning in humans. 
The cu rrent study was undertaken as part of  a target population comparative 
study which co mmenced i n Fe bruary 2008 an d which m ain ai m was t o 
investigate bi ological m arkers associated w ith h igher sym pathetic nervous 
system act ivity in ur banised t eachers with a sp ecific co ping st yle, viz.  t he 
SABPA p roject ( Sympathetic activity and Ambulatory Blood Pressure i n 
Africans). 
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The desig n and  methodology was to optimise an e xisting high per formance 
liquid ch romatography electrochemical det ection m ethod f or t he quant ification 
of catecholamines and their metabolites in rat brain tissue for the quantification 
of M HPG in hum an saliva. The new  optimised m ethod was validated a nd 
applied to human saliva samples. 
The m ajor ch anges that w ere m ade f or t he new  opt imised method w ere t he 
following: the organic part of  the mobile phase was changed from 10% to 4% 
acetonitrile. The pH of the mobile phase was changed from pH 3.2 to pH 4.1. A 
longer co lumn w as used an d the f lowrate was changed f rom 1. 0 ml/min to  
0.85 ml/min. The injection volume was changed from 100 µl to 5 µl. The sample 
preparation for the sa liva samples was also di fferent from the rat brain t issue 
sample preparation. 
The key findings were that the new method was sensitive and sp ecific enough 
for t he qu antification of  MHPG in hum an sa liva samples. The va lidation 
parameters showed t hat t he m ethod was sensitive, s pecific and r eliable. The 
method could detect MHPG levels in human saliva f rom as low as 3.85 ng/ml 
and w ith a  l ower limit of  det ection of  1 ng /ml. The r egression value f or t he 
linearity curve w as r2 = 0.998. The accu racy and pr ecision r esults gave 
percentage relative standard deviation values less than 15%. The %  recovery 
results were al l a bove 80 %, which is  good f or the anal ysis of endoge nous 
compounds in biological samples. 
The r ecommendations include t hat i n or der to i ncrease t he s ensitivity and 
selectivity of the method even more, the amperometric electrochemical detector 
can be  r eplaced w ith a co ulometric electrochemical det ector or  a co ularray 
electrochemical detector. The rest of the unknown peaks in the saliva samples 
should be  i dentified, beca use i t m ay broaden t he r ange of  endogen ous 
compounds that may be analysed through this method. 
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Een van die grootste uitdagings in biomediese tegnologie is om nuwe tegnieke 
te vind vir  die deteksie, diagnose en di e interpretasie van komplekse menslike 
siektetoestande. Die behoefte vir die analise van endogene biologiese merkers 
van ve rskillende s iektetoestande st imuleer die vo ortdurende soeke na m eer 
effektiewe en se nsitiewe an alitiese m etodes wat ui teindelik tot bet er 
behandeling sal bydra. 
Die ontwikkeling van betroubare bio-analitiese metodes is van u iterste belang 
vir die totale sorg van ‘n pasiënt en as so ‘n metode ontwikkel ter stawing van 
die di agnose van ve ral psigi atriese t oestande ( bv. s tress-verwante 
siektetoestande, depr essie e ns.) kan w ord, sal d ie v oordele onberekenbaar 
wees. 
In die sentrale senustelsel kom katesjolamiene as natuurlike chemiese middels 
genaamd neurotransmitters voor en i n di e bl oed f unksioneer hulle as hulle 
hormone wat deur  die adrenale medulla vrygestel word. Hulle is  belangrik vir 
die goeie funksionering van die brein en liggaam want hulle herlei seine tussen 
senuselle. Norepinefrien is een van die primêre katesjolamiene en 3-metoksi-4-
hydroksifenielglikol ( MHPG) is een va n d ie metaboliete daarvan. V erskeie 
studies het di e be lang va n M HPG i n sp eeksel as ’n bi ologiese m erker vir  
veranderinge in die sentrale en perifere katesjolamienmetabolisme ondersteun, 
terwyl d it van so mmige asp ekte van ve rstandelike f unksionering in di e m ens 
kan weerspieël. 
Hierdie studie, wat in Februarie 2008 beg in het , is onderneem as deel van ‘n 
vergelykende studie, met ‘n teikenpopulasie waarvan die hoofdoel was om die 
biologiese m erkers van hoër aktiwiteit v an di e si mpatiese senustelsel in 
verstedelikte onderwysers met ‘n spesifieke oorlewingstyl te ondersoek (nl. die 
SABPA-projek). 
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Die hoofdoelwit was die optimalisering van ‘n bestaande hoëverrigting vloeistof- 
chromatografiese el ektrochemiese det eksiemetode om  M HPG i n menslike 
speeksel monsters te kwantifiseer. 
Die o ntwerp en  metodiek was die o ptimalisering va n ‘ n bestaande hoë 
verrigting vloei stofchromatografiese el ektrochemiese det eksiemetode vir d ie 
kwantifisering van katesjolamiene en h ul metaboliete in rotbreinweefsel vir d ie 
kwantifisering van MHPG in menslike speeksel. Dit het  ook die validering van 
die nu we geoptimaliseerde m etode en di e t oepassing v an di e m etode op 
menslike speekselmonsters behels. 
Die b elangrikste veranderinge w at vir  di e nuw e g eoptimaliseerde m etode 
gemaak is, was die volgende: die organiese gedeelte van die mobiele fase is 
van 10% na 4% asetonitriel verander. Die pH van die mobiele fase is vanaf pH 
3.2 na pH 4.1 aangepas. ‘n Langer kolom is gebruik en die vloeisnelheid is van 
1.0 ml/min na 0. 85 ml/min verander. D ie i nspuitingsvolume i s vanaf 100 µl na 
5 µl verander. Die voorbereiding van die speekselmonsters was ook anders as 
dié van die rotbreinweefsel. 
Die sleutelbevindinge was dat die nuwe metode sensitief en sp esifiek genoeg 
vir di e k wantifisering va n MHPG in m enslike sp eekselmonsters is. Die  
validasieparameters het get oon dat  di e m etode se nsitief, sp esifiek en 
betroubaar is. Die metode kon MHPG-vlakke in menslike speeksel tot so laag 
as 3.85 ng/ml met ‘n ondergrens van 1 ng/ml bepaal. Die regressiewaarde van 
die lineêre kurwe was r2 = 0.998. Die akkuraatheids- en presisieresultate het ‘n 
relatiewe persentasie st andaard af wyking va n m inder as 15% gegee. D ie 
persentasie her winning w as meer as 80%, wat goed i s vir d ie ana lise van 
endogene komponente in biologiese monsters. 
Die aanbevelings is onder meer dat die metode se sensitiwiteit en selektiwiteit 
verhoog kan word de ur di e am perometriese el ektrochemiese det ektor m et ‘ n 
coulometriese elektrochemiese det ektor of  ‘ n C oulArray® elektrochemiese 
detektor te vervang. Die ander onbekende pieke in die speekselmonsters kan 
geïndentifiseer w ord, w ant di t k an die r eeks endogene ko mponente vergroot 
wat deur die metode ontleed kan word. 
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Introduction 
Chapter 
1 
 
One of  t he gr eatest ch allenges in t he f ield of bi omedical t echnology is to 
find new  t echniques t o det ect, di agnose and i nterpret co mplex hum an 
disease conditions. The need to analyse or measure endogenous biological 
markers related to different diseases has stimulated the continuous search 
for m ore ef fective and se nsitive anal ytical m ethods which will eventually 
also contribute to better therapy.  
The development of reliable bio-analytical methods is of utmost importance 
for the total care of a patient and if such a method can be developed to aid 
in t he di agnosis of esp ecially psychiatric co nditions ( e.g. st ress-related 
disorders, depression, etc.) the benefits will be incalculable.  
The cu rrent st udy was undertaken as part of  a target po pulation 
comparative study that commenced in February 2008 and whose main aim 
was to i nvestigate bi ological m arkers associated w ith hi gher sym pathetic 
nervous system act ivity in urbanised teachers with a specific coping style, 
viz. the S ABPA (Sympathetic activity and Ambulatory Blood Pressure i n 
Africans) project (see appendix B: Information and consent form and Ethics 
approval certificate of the SABPA project). 
The se arch f or a non-invasive m ethod t o det ect biological m arkers 
associated with higher sympathetic nervous system activity in humans is a 
major pr oblem, esp ecially when i t co mes to st ress and st ress-related 
disorders. 
Everly and Lating (2002) stated: "If we cannot reliably and validly measure 
the hum an st ress response, w hat degr ee of  cr edibility do we p lace up on 
investigations into its phenomenology?" 
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In order to get  an i ndication of  the levels of biological markers associated 
with st ress-related di sorders, viz.  t he ca techolamines, a f ew m ethods are 
described i n t he literature t o quant ify t hese s ubstances and t heir 
metabolites (Okumura et al., 1997; Yang et al., 1997; Yamada et al., 2000).  
Most of  t hese m ethods however i nvolve i nvasive sampling pr ocedures 
(plasma, C SF) or  ur ine sa mples. W hile so me of  t he catecholamines and 
their metabolites can be detected in saliva (Yamada et al., 2000; Kennedy 
et al., 2001), we aimed to develop a novel bio-analytical method to quantify 
the levels of the primary catecholamine metabolite in saliva, viz. 3-methoxy-
4-hydroxyphenylglycol (MHPG). 
AIM 
The ai m o f t he cu rrent st udy was therefore t o deve lop or  opt imise a n 
existing m ethod t o quantify 3-methoxy-4-hydroxyphenylglycol ( MHPG) 
levels in human saliva. 
While we have a validated and reliable method in place in our laboratory for 
the det ermination of ca techolamines and m etabolites in brain an d 
cerebrospinal fluid (Coetzee et al., 2006; Harvey et al., 2006; Marais et al., 
2006), we hypothesised that this method can be m odified and optimised to 
be se nsitive and  specific to det ermine 3 -methoxy-4-hydroxyphenylglycol 
(MHPG) levels in human saliva samples. 
OBJECTIVES 
The objectives of the current study include the following: 
1. To optimise an existing HPLC e lectrochemical detection method for 
the quantification of catecholamines and their metabolites in rat brain 
tissue f or t he quant ification of 3 -methoxy-4-hydroxyphenylglycol 
(MHPG) in human saliva. 
2. To va lidate t he new  optimised m ethod a ccording t o poi nt 2. 9 in 
chapter 2. 
3. To apply this validated method to human saliva samples. 
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RELEVANCE 
This new method can be ut ilised as a screening procedure to monitor the 
body’s reaction in response to sympathetic activity and as such it may be of 
value t o d etermine the bo dy’s response t o st ress and ai d as  a di agnostic 
tool for stress-related disorders. Pharmacologically, it may be of value in the 
search f or nove l an d m ore ef fective t reatment r egimens for st ress and 
stress related disorders such as anxiety, post-traumatic-stress-disorder and 
depression. 
RESEARCH LAYOUT 
The study was divided into three phases:  
• Optimising the existing HPLC electrochemical detection method. 
• Validation of the new method in saliva. 
• Application o f the v alidated m ethod t o human sa liva sa mples 
obtained in the SABPA project. 
In or der to ach ieve t he ai ms of  the st udy, a n HPLC co upled t o an  
electrochemical det ector w as used t hroughout t he st udy. H uman sa liva 
samples collected from participants in the SABPA project were finally used 
to eva luate t he ap plicability of t he ne w m ethod. N ot al l t he co llected 
samples were anal ysed i n t he cu rrent st udy, b ut onl y five samples 
representative of the group. 
A t horough di scussion of  t he available a nd r elevant l iterature r egarding 
analysis of ca techolamines, esp ecially the m etabolite MHPG i n bi ological 
samples with t he f ocus on sa liva, as well as current methods available t o 
quantify MHPG in this matrix is given in the following chapter.  In chapter 3 
the research methodology followed in this study is described in detail, while 
discussion of the results and conclusions from the study is given in chapters 
4 and 5 .  This dissertation is co ncluded w ith t wo appendices i n which 
appendix A  consists of  a su mmary on t roubleshooting usi ng HPLC with 
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electrochemical det ection and  appendix B includes information on t he 
SABPA project and the Ethics approval certificate. 
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Literature Review 
Chapter 
2 
 
In medical sci ence there i s a  co nsiderable need for new  and bet ter 
analytical methods to det ect and qua ntify endogenous biomarkers in 
biological sa mples in or der to diagnose a nd t reat h uman di sease st ates. 
There are a few important key aspects when a new method is developed or 
a cu rrent m ethod i s optimised. Knowledge of  the endogeno us biomarker, 
the biological sample matrix, the analytical instrument, previous developed 
methods, s ample co llection, sa mple pr eparation and pr evious r esults are 
essential. The validation of the new analytical method is also very important. 
The focus of the current study was on the development and opt imisation of 
a m ethod for t he determination of  M HPG ( an i mportant ca techolamine 
metabolite) in saliva. 
2.1 3-Methoxy-4-hydroxyphenylglycol (MHPG) 
In the central nervous system (CNS) catecholamines are naturally occurring 
chemicals called neu rotransmitters and i n t he bl ood t hey are hormones 
secreted by the adrenal medullae. They are very important for proper brain 
and body  function because they relay signals between nerve ce lls. These 
neurochemicals play an i mportant r ole i n a per son’s mental, physi cal and  
emotional status. They also affect f unctions like sleep, behav iour, m ood, 
digestion, weight, focus and learning ability. When there are imbalances of 
these neur ochemicals i t ca n usually be t raced t o st ress or a poor di et. 
Genetics and env ironmental t oxins can also ca use i mbalances. W hen a  
patient ha s an i mbalance it w ill usu ally involve m ore t han o ne 
neurotransmitter (Marcantel, 2008). 
The 3 m ain ca techolamines with t heir m etabolites are dopamine (DA, 
metabolites: DOPAC, HVA), norepinephrine (NE) and epinephrine (Epi). 3-
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Methoxy-4-hydroxyphenylglycol (MHPG, MOPEG) is a major metabolite of  
the degradation of NE in the CNS. The aldehyde intermediate DHPG (3,4-
dihydroxyphenylglycol), produced by the action of  the enzyme monoamine 
oxidase (MAO) on nor epinephrine is reduced to a g lycol with the aid of the 
enzyme, catechol-O-methyltransferase (COMT).  
 
Figure 1 : Synthesis of M HPG (Degradation of  N E). Catecholamines: DA 
(dopamine), N E ( norepinephrine), EPI ( epinephrine), Metabolites: D opac 
(3,4-dihydroxyphenylacetic acid), H VA ( homovanillic acid) , D HPG ( 3,4-
dihydroxyphenylglycol), M N ( metanephrine), N MN ( normetanephrine), 
MHPG (3 -methoxy-4-hydroxyphenylglycol), V MA (v anillylmandelic acid), 
Enzymes and c o-factors: D βH (d opamine-β-hydroxylase), P NMT 
(Phenylethanolamine N -methyltransferase), MAO ( monoamine oxidase), 
COMT (catechol-O-methyltransferase), AD (a ldehyde dehydrogenase), AR 
(aldehyde reductase), A DH ( alcohol d ehydrogenase) (Eisenhofer et al ., 
2004). 
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Figure 2: MHPG molecule. 
Catecholamines and t heir m etabolites are classi fied as either basic or 
acidic, but MHPG is a neutral molecule (molar mass of 184.19). It is readily 
released into the bloodstream and cerebrospinal fluid (CSF) and therefore a 
blood or a CSF sample may be an indication of recent sympathetic nervous 
system activity (Cooper et al., 2003; Li et al., 2006). 
In h uman bl ood, catecholamines and t heir metabolites ar e water-soluble 
hormones. T hey are di ssolved i n t he plasma and t ransported f rom t heir 
sites of syn thesis to t arget t issues throughout t he body.  Here t hey diffuse 
out of  the blood capillaries, into the interstitial f luid, and ul timately into the 
target cells (Guyton et al., 2005). 
Hormones that are commonly measured in plasma are for example steroids, 
non-steroids, peptides and protein hormones but they can also be detected 
in sa liva. The exist ence of  a co nnection b etween t he cir culating hor mone 
levels and t he hormone l evels i n saliva must f irst be def ined before any 
significance can be a ttached to the measured hormone level in the saliva. 
The information of the origin of the salivary hormone allows for a definition 
of its role and co nnection w ith pat hological and  physi ological st ates 
(Chiappin et al., 2007).  
The correlation of MHPG levels in the d ifferent bodi ly fluids, the bl ood 
(plasma) and s aliva i s ve ry i mportant and m ay give va luable information 
about the sympathetic activity in the body as well as possible pathological 
states. Mitoma (2008) and coworkers reported on a variety of studies that 
connected increased M HPG p lasma l evels with p sychological st ress, 
depressed patients and the state of anxiety of a pat ient. They also found in 
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their ow n study that subjects with a gr eater psych ological j ob st ress had 
higher p lasma M HPG l evels than su bjects who su ffered l ess from 
psychological job stress. 
All three major catecholamines can be detected in saliva with levels varying 
from 250 up to 800  pg/ml, but  their or igin is still largely unknown. P art of  
salivary catecholamines seems to or iginate from pl asma via diffusion a nd 
part of  i t i s derived f rom sympathetic nervous terminals via direct release. 
Due t o unce rtainty of t heir or igin, concentrations of t he m ajor 
catecholamines in sa liva ar e usually poorly correlated w ith catecholamine 
levels in plasma (Chiappin et al., 2007). 
Previous studies did, however, find good c orrelations between plasma and 
saliva catecholamine metabolite levels, especially MHPG (Yang et al., 1997; 
Yamauchi et al., 2001). Yamauchi and co-workers reported on a number of 
studies in wh ich the MHPG l evel i n s aliva co rrelated signi ficantly with its 
level i n pl asma, while other studies confirmed t hat ca techolamine 
metabolites of NE in saliva mainly result from diffusion from the bloodstream 
into the saliva. Strong correlations have also been reported for levels of the 
NE metabolite MHPG between p lasma and sa liva, with the total levels not 
higher in the saliva than in the plasma. MHPG levels in saliva may therefore 
be used as a useful and non-invasive biomarker to detect changes in the 
central an d per ipheral catecholamine m etabolism (Yamada et al ., 2000 ; 
Kennedy et al., 2001; Yamauchi et al., 2001). 
Yamada and co -workers reported in 2 000: “ The co ncentration of sa liva 
MHPG seems to be regulated by a balance between peripheral sympathetic 
(noradrenergic which su pplies M HPG t o sa liva) and p arasympathetic 
(cholinergic which regulates the volume of saliva) nerve activities. Thus, the 
greater changes in saliva MHPG level response to anxiety or st ress could 
be det ected i n co mparison w ith t hose i n plasma M HPG l evel, beca use 
anxiety or st ress should reduce the vo lume of  sa liva, resulting in a r obust 
increase in the concentration of saliva MHPG”. Therefore the MHPG levels 
detected i n sa liva appeared t o be non -specific and r epresentative of  t he 
anxiety state in humans (Yamada et al., 2000). 
Chapter 2: Literature Review 9 
 
MHPG co ncentrations in bot h pl asma an d C SF ar e f requently used t o 
assess noradrenergic metabolism in clinical studies (Reuster et al ., 2002) . 
Recent studies have sh own t hat M HPG ca n be r eproducibly assayed in 
saliva. W hile the brain co ntributes about 30%  o f plasma M HPG an d 
furthermore 50%  of  plasma M HPG i s converted t o V MA, sa liva M HPG 
ultimately reflects both pl asma M HPG l evels and l ocal M HPG syn thesis 
(Reuster et al ., 2002). Significant correlations were found between plasma 
and sa liva M HPG c oncentrations, f urther co nfirming r esults of pr evious 
studies that salivary MHPG can reflect plasma MHPG levels (Reuster et al., 
2002). These results provide gr ounds to assu me t hat sa livary MHPG ca n 
indeed also reflect C SF M HPG l evels and enhanc e t he ut ility of sa livary 
MHPG m easurements as a n on-invasive m eans for i nvestigating t he 
noradrenergic system in a clinical setting (Reuster et al., 2002).  
Several studies in which the potential clinical benefits of measuring MHPG 
levels in p lasma, sa liva and C SF were investigated a s indicators of br ain 
noradrenergic activity related to dr ug t herapy and  ne uropsychiatric 
disorders have been reported (Reuster et al., 2002). Li et al. (2006) reported 
e.g. that while the level of MHPG in plasma reflects noradrenergic neuronal 
tone in humans the MHPG level in saliva correlates significantly with levels 
thereof in pl asma an d CSF and i t ma y therefore be a use ful m arker for 
detecting changes in the central and per ipheral catecholamine metabolism 
while also reflecting some aspects of mental functioning in humans. 
Hormone quantities required to control m ost metabolic and endocr ine 
functions in t he body are i ncredibly small and  i n t he bl ood t heir 
concentrations range from as little as 1 picogram (which is 1 x 10-12) up to at 
most a few micrograms (1 x 10-6) per millilitre of blood. The secretion rates 
of the various hormones are extremely small, and are usually measured in 
micrograms or milligrams per day (Guyton et al., 2005). 
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2.2 The sample matrix - Saliva 
Analytical s tudies done on saliva are not  nove l, but t he physi ological 
importance of sa liva as a sa mple m atrix has only been r ecognized l ately. 
The pace of salivary research has accelerated in the past 50 years because 
of new  techniques that i lluminate t he b iochemical an d phys ical-chemical 
properties of saliva (Schipper et al., 2007). The finding that saliva was filled 
with hundreds of components that may serve to detect even more systemic 
diseases or evidence of exposure to various harmful substances, as well as 
providing biomarkers of heal th a nd di sease st atus, ca used t he i nterest in 
saliva t o increase e ven m ore. Nowadays, due t o novel approaches that 
include m etabolomics, genom ics, pr oteonomics and bioinformatics the 
research field of sa liva i s rapidly advancing. Bu t, due t o i ts complex 
biochemical and physical-chemical properties and its inherent variability and 
instability, t he usa ge of sa liva as a research m aterial m ay pose a f ew 
problems (Schipper et al., 2007). 
The assa y of hum an sa liva as a di agnostic tool has implications for bot h 
basic and cli nical i nvestigations and has provided an e xtra t ool f or 
identification of disease processes and disorders (Chiappin et al., 2007). 
The bl ood f low t o sa livary glands is increased by parasympathetic and 
peptidergic stimulation and therefore enhances saliva formation. The levels 
in sa liva o f co mpounds such as catecholamines and t heir m etabolites 
derived from the blood can therefore provide a useful index of blood levels 
of the same compounds (Kennedy et al., 2001). 
There are quite a few advantages of using saliva rather than blood or urine 
as a di agnostic tool. Thi s includes a s impler, non -invasive and l ess 
traumatic collection method t han t hat of  bl ood or  ur ine, esp ecially for 
infants, ch ildren a nd the el derly. Ther e ar e al so m any circumstances in 
which t he sampling o f bl ood an d ur ine i s not possible (Chiappin et al ., 
2007). 
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The oral fluid in humans is called saliva and it is an exocrine secretion with 
a pH range from 6.2 to 7.4, with the higher pH caused by an increased rate 
of se cretion. Saliva consists mainly of  water, a va riety of el ectrolytes, 
mucus, proteins and enzymes (Höld et al., 1995; de Almeida et al., 2008). 
Human saliva production per day is from 1 to 1.5 litres. Its primary purpose 
is to ai d i n digestion of  f ood, t he pr otection and l ubrication o f t he or al 
tissues, t he di lution of certain substances ( for ex ample s ugars) and t he 
mechanical cleansi ng of  t he m outh (Höld et al ., 1995 ; de A lmeida et al ., 
2008). It posse sses several f unctions involving hom eostasis and 
maintaining or al he alth t hrough an act ive protective r ole (Chiappin et a l., 
2007). Thi s oral f luid or iginates f rom m ainly three pa irs of m ajor sa livary 
glands ( parotid, su blingual and  su bmandibular) and  al so f rom a l arge 
number of minor salivary glands (Chiappin et al., 2007). 
The compositional analysis of saliva can be an important tool for physiology, 
pathology and for the diagnosis of oral and systemic diseases. There are a 
variety of inorganic, organic, non-protein, protein or polypeptide compounds 
in saliva, as well as hormones and l ipid molecules (Chiappin et al ., 2007). 
The interrelationship between salivary hormones and the cir culating ones,  
especially catecholamines (Chiappin et al., 2007) emphasises the fact that 
saliva c ould t herefore be an important di agnostic tool f or r esearch i n a 
variety of medical research fields. 
The co mposition and  out put of  saliva de pend on t he autonomic nervous 
system’s activity. The sym pathetic system co ntrols the se rous part of  t he 
glands whereas both the parasympathetic and sympathetic systems control 
the m ucous part (Chiappin et al ., 2007) . Th e quantity, visco sity and i onic 
composition of saliva can be modified by pharmacological and neural stimuli 
(α – β adrenergic and cholinergic) and t he protein concentrations can vary 
as well (Chiappin et al., 2007). 
Upon parasympathetic stimulation, a hi gh f low of  sa liva t hat co ntains low 
levels of organic and inorganic compounds results. Sympathetic stimulation 
produces saliva which i s low in vo lume and has high co ncentrations of 
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protein and potassium. Food presence may affect the salivary composition 
in the mouth. Fol lowing food intake, se lective protein release is stimulated 
thereby increasing the total amount of proteins and the enzyme α-amylase 
in saliva (Chiappin et al., 2007). 
There are primarily three processes involved in the clearance of compounds 
from plasma into saliva. The f irst is ultra filtration through the gap j unctions 
in bet ween ce lls of t he se cretory units (the i ntercellular ne xus). The on ly 
molecules that w ill f ilter t hrough ar e m olecules with a m olecular weight 
smaller than 1900 g/mol. The molecules involved here are water, ions, and 
hormones (such as catecholamines and s teroids). The co ncentration of  
these m olecules in t he sa liva is 300 t o 3000 t imes lower t han i n plasma 
(Chiappin et al., 2007). The second is transudation of the compounds in the 
plasma i nto t he or al cavity and t hirdly is through ce llular m embranes by 
means of selective transport (Chiappin et al., 2007). 
2.3 Analytical methods for catecholamine detection 
There ar e se veral anal ytical methods described i n l iterature t o det ect 
catecholamines and t heir m etabolites i n hum an sa liva, viz. radio-
immunoassay  pr ocedures, g as chromatography-mass spectrometry 
(GCMS) (Yamada et al ., 2000 ), high performance l iquid c hromatography 
(HPLC) coupled t o a  f luorescent or  ul traviolet detector (Okumura et al ., 
1997), and HPLC coupled to a electrochemical detector (ECD) (Yang et al., 
1997). 
HPLC co upled t o a n el ectrochemical d etector i s the preferred analysis 
method, beca use it is more se nsitive t han ul tra-violet or  f luorescent 
detectors, and al so much ch eaper t han G CMS and r adio-immunoassay 
procedures. I t i s also a direct analysis method an d no  der ivatisation 
procedures are needed. 
The method which w ill be opt imised in this par ticular study for analysis of 
salivary catecholamines, and specially MHPG,  is an HPLC-ECD method for 
quantifying catecholamines and their metabolite levels in brain t issue, CSF 
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and plasma and has been used in our department for more than 20 ye ars 
(Coetzee et al., 2006, Harvey et al., 2006, Marais et al., 2006). 
2.4 High p erformance l iquid c hromatography 
coupled to electrochemical detection 
High performance liquid chromatography (HPLC) 
The method or technique rapidly becoming the choice for analysis and the 
separation of  di fferent m atrixes in m any r esearch areas today is high 
performance liquid chromatography (HPLC) (McMaster, 2007).  
HPLC coupled to a variety of different detectors is a major analytical tool in 
biomedical and pharmacological r esearch t oday. Th e f ast and  ef fective 
ways for the development of analytical HPLC methods is undertaken more 
efficiently with a t horough und erstanding of H PLC p rinciples, t heory and 
instrumentation (Kazakevich et al., 2007). HPLC is a technique that al lows 
the analyst to separate complex mixtures of analytes on a chromatographic 
column connected via a pump and an autosampler to a specific detector in 
order t o det ermine t he num ber, i dentity and quant ity of t hose anal ytes. 
(Huber, 2009). 
Basic theory of high performance liquid chromatography 
HPLC is the chromatographic technique widely used in analytical research. 
The t ype of ch romatography which is mostly used i s reversed-phase 
chromatography, w hich i s t he r everse of  t he nor mal-phase m ode ( Hanai, 
1991). HPLC utilises a liquid mobile phase for the separation of components 
(analytes) of  a so lution ( sample). The sa mple with analytes are prepared, 
and t hen f orced t o f low t hrough a ch romatographic co lumn ( stationary 
phase) under a hi gh pressure. In reversed-phase HPLC the retention of  a  
component on t he co lumn is mainly the r esult of  hyd rophobic interactions 
between t he component and t he hyd rophobic stationary phase surface of 
the co lumn. In t he c ase of  ca techolamines and t heir m etabolites, which 
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comprise of acidic, basic and neutral compounds, reversed-phase ion-pair 
HPLC is used. Here the formation of  neut ral ion pa irs, with the aid of  ion-
pairing ag ents (e.g. sodium 1 -heptanesulfonate), which i s ad ded t o t he 
mobile pha se, helps to se parate t he di fferent co mpounds on a  r eversed-
phase column (Lim, 1991; Lough and Wainer, 1996). 
The reverse-phase columns a re usually packed w ith silica-based so lid 
particles in w hich oct adecylsilyl (C18) or  o ctylsilyl ( C8) gr oups had bee n 
chemically bonde d t o t he si lica su rface. In t he column, th e mixture is  
resolved i nto i ts separate co mponents following m igration of  t he anal ytes 
through t he co lumn. The i nteraction of  t he so lutes (analytes) with m obile 
and stationary phases can be manipulated through different choices of both 
solvents and stationary phases. As a result, HPLC acquires a high degree 
of ve rsatility not f ound i n ot her chromatographic systems and i t has the 
ability to easily separate a wide variety of chemical and biological samples. 
Each analyte is shown as a single peak on the final chromatogram as long 
as there i s good se paration b etween a ll t he anal ytes i n t he sa mple (Lim, 
1991; Lough and Wainer, 1996). 
Figure 3:  Simple diagram of  a n HPLC syst em w ith am perometric 
electrochemical detector (AECD). 
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Currently, m ost H PLC i nstruments are co nnected t o a co mputer w ith a 
software pr ogram t hat co nverts the anal og signa l f rom t he d etector t o a 
digital signal in order to give an electronic interpretation of  the data found. 
The out put i s in t he f orm of  a c hromatogram (see f igure 3) . In HPL C the 
solvents, mobile phase, stationary phase, pH and t emperature play a very 
important role in the outcome of how the different analytes will separate into 
individual peaks on the final chromatogram picture. 
Electrochemical detection 
In electrochemical detection the oxidat ion or reduction of  an anal yte in the 
redox process is the resulting current monitored in ampere in a flow-through 
cell where the applied potential (volts) across a working electrode surface is 
held constant (GBC Scientific Equipment P ty, 1995 ; Lough and Wainer, 
1996; ESA, Inc., 2004). Thus, this technique can be utilised for analytes that 
are r eadily oxidizable or  r educible or  i onic e.g. proteolytic organic 
compounds such as amines (catecholamines), ca rboxylic acids, i norganic 
ions, alcohols, phenols and thiols (Kazakevich et al., 2007). There are two 
kinds of el ectrochemical det ection m ethods available, viz. amperometric 
and co ulometric.  T his study will ut ilise am perometric electrochemical 
detection. 
Basic t heory o f amperometric electrochemical d etection 
(AECD) 
Amperometric electrochemical d etection i s based on t he m easurement of  
the current resulting from an oxidation or reduction reaction of the analyte at 
a su itable electrode. When an  amperometric electrochemical detector i s 
used, the potential (in volts) is kept constant and the current produced from 
the electrochemical reaction is then measured in ampere (micro- or nano- or 
pico-ampere) - the term used for this process is potentiostatic amperometry. 
The level of the current (and the area or height of the analyte's peak on the 
chromatogram) i s directly proportional t o t he co ncentration of  t he anal yte. 
The el uent ( or m obile phase ) t hat f lows through t he el ectrochemical ce ll 
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should co ntain e lectrolytes (analytes) of  a sa mple and b e e lectrically 
conductive. M ost of  t he ana lytes require pH adj ustments to t he m obile 
phase t o b e su ccessfully detected (GBC Scientific Equipment P ty, 1995 ; 
Lough and Wainer, 1996). 
The ar eas of  app lication of  e lectrochemical det ection ar e r estricted. 
Sensitivities for compounds such as phenols, catecholamines, nitrosamines, 
and organic acids are in the pico-mole (nano-gram) range. The  specificity 
and sensitivity make it a very useful tool for monitoring these compounds in 
complex m atrices such as body fluids and nat ural pr oducts. The pur ity of 
the el uent i s very important, because t he pr esence of  ox ygen, m etal 
contamination and  ha lides may cause si gnificant bac kground current and  
interferences (GBC Sci entific Equipment P ty, 1995;  Lough and  Wainer, 
1996). 
Figure 4 : Principle of  el ectrochemical det ection i n an  el ectrochemical f low 
cell. The r edox reaction takes place inside the electrochemical f low ce ll of 
the electrochemical detector (Bioanalytical Systems, Inc. 1994). 
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Oxidation r eaction at t he electrode of an  amperometric 
electrochemical detector 
The reaction of a specific analyte that takes place at the electrode is called 
the oxidat ion r eaction. Thi s is where t he anal yte ch ange from i ts reduced 
form to  i ts o xidized f orm and d onates electrons to t he el ectrode. Thi s 
reaction i s ca used b y the appl ied pot ential of  the e lectrode. The ne xt 2 
figures show the o xidation r eaction f or n orepinephrine and its metabolite 
MHPG. 
 
 
Figure 5:  O xidation r eaction of  norepinephrine (Lough and W ainer, 1996 ; 
Flanagan et al., 2005). 
 
 
Figure 6:  O xidation reaction of  M HPG (as adapted f rom examples in 
literature, Lough and Wainer, 1996; Flanagan et al., 2005 and Robinson et 
al., 2008). 
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2.5 Method development or the optimisation of an 
HPLC method 
Substances that are bi omedically important in hu man sa mples have a  
variety of structures with different su bstituents. They  have  aromatic rings, 
aliphatic rings, long alkyl chains and some are acidic or basic compounds. 
These d ifferences make it ve ry difficult t o deve lop o r opt imise an HPLC 
method of  bi omedically important co mpounds. A lthough m any related 
reports have been published, there is still no simple solution for separating 
such complicated mixtures in HPLC (Lim, 1991). 
When dev eloping a new m ethod or  optimising an e xisting H PLC m ethod, 
knowledge about  t he anal yte, t he sa mple m atrix, t he i nstrumentation and  
the existing methods in literature are very important.  
Important i nformation of  t he a nalyte is the siz e of  t he m olecule, t he 
structure, purity, so lubility, st ability, pr esence i n t he sa mple, syn thesis, 
metabolism and pr otein bi nding (Kelly et al ., 2007)  ( discussed in 2. 1). 
Important information of  t he sa mple m atrix i s the b iological or igin, pH , 
composition and stability (discussed in 2.2). It is also very important to know 
the working principle of the instrumentation (discussed in 2.4). 
During HPLC analysis the factors in table 1 are important for good analysis, 
as they may all h ave an ef fect on t he elution of  t he anal ytes through t he 
HPLC co lumn and al so on the base line d etected by the det ector (in t his 
case el ectrochemical det ection). These  f actors all t ogether pl ay an 
important r ole to pr oduce a va lid chromatogram f or a sp ecific analyte o r 
group of analytes. The influence of the different contributing factors on the 
resulting chromatogram is shown in the next table. 
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Table 1:  Influences of  di fferent cont ributing f actors on t he r esulting 
chromatogram 
Factor Change 
Effect on peak  el ution 
through the HPLC column 
Room temperature 
Increase Faster peak elution 
Decrease Slower peak elution 
Mobile phase pH 
More acidic 
Faster pe ak elution for basic  
analytes 
More alkaline 
Slower pe ak elution for acidi c 
analytes 
% Organic content 
More Faster peak elution 
Less Slower peak elution 
HPLC column length 
Longer Slower peak elution 
Shorter Faster peak elution 
HPLC column 
diameter: 
The sm aller 
the diameter 
Produces better sensitivity and 
resolution 
Mobile phase flowrate 
Higher Faster peak elution 
Lower Slower peak elution 
Factor Change Effects on the baseline 
Room temperature 
Increase Upwards drift of baseline 
Decrease Downwards drift of baseline 
Mobile phase flowrate 
Too high 
Analytes pass electrode t oo 
quickly and ca use poor 
sensitivity 
Too Low 
Analytes pass electrode t oo 
slowly and ca use an overload 
on electrode 
Sample injection 
volume 
Too much 
Will f lood t he f lowcell, peaks to 
big 
Too little Peaks too small or not detected 
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2.6 Sample collection and preparation 
Human saliva samples can usually easily be collected in special salivettes. 
It is however very important that the patient receives detailed information of 
the co llection pr otocol, su ch as  the ex act timing of  sa mpling. P atients 
should not brush their teeth and also avoid any food and f luid intake for at 
least 30  minutes before sa mple co llection. They must al so r inse t heir 
mouths with distilled water just before the sample is collected (Chiappin et 
al., 2007). 
There are various ways of collecting saliva, from sucking it up with a pipette 
to ch ewing a co tton swab. The re ar e se veral or al f luid co llectors and 
commercial device s available f or co llecting sa liva sa mples, t he one t o b e 
used in this study, are polyester salivettes. This device is most commonly 
used and consists of a st erile co tton dent al r oll i nside a s terile pol yester 
tube called a salivette. This product is commercially available from Sarsted 
(Newton, NC) (Chiappin et al., 2007). 
 
 
 
 
 
 
 
 
 
Figure 7: Polyester salivette with cotton roll. 
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The co tton r oll is placed inside the pat ient’s mouth w ith a st erile f orceps. 
The pat ient t hen gent ly chews it f or 2 m inutes, w here af ter i t i s r emoved 
again with a sterile forceps and placed into the polyester tube. 
After sa mple co llection t he sa liva sp ecimen sh ould be sn ap f rozen with 
liquid nitrogen, kept on ice and immediately stored at -80°C to maintain the 
sample integrity until the day of sample analysis (Chiappin et al., 2007). 
2.7  Internal standard 
The i nternal st andard i s a t est su bstance w hich i s added in a kn own 
concentration to bot h t he ca libration st andards and t est sa mples. The 
internal st andard i s used t o f acilitate i n t he ca lculation of  t he unkn own 
concentration of t he anal yte in t he t est sa mples during the qual itative 
identification and/ or q uantitative determination of  t he s ample co mponents. 
The t est su bstance used as the i nternal st andard must be i n st ructure 
similar to the test compounds and it must be a st able substance (Garofolo, 
2004). The i nternal st andard a lso se rves as a m arker or  i nsurance in t he 
way that when t here i s something w rong w ith t he syst em or  anal ysis 
procedure both the internal standard and analytes peak would not show on 
the chromatogram. But when there is nothing wrong with the system or the 
analysis procedure a nd onl y the i nternal st andard’s peak show on t he 
chromatogram and no t t he anal yte of  interest’s peak that m eans that t he 
sample does not contain any of the analytes of interest or the concentration 
of the analyte is below the detection limit. 
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2.8 Previous results from literature 
Table 2: Previous results 
Author MHPG level in saliva Comment 
Yang et al., 1997 7.03 ± 3.26 ng/ml (n = 10) HPLC-ECD  
Yamada et al., 
2000 
Men and women (10.7 ± 3.1 ng/ml, 
n = 59 and 10.3 ± 3.6 ng/ml, n = 
137) in normal controls. 
Patients with anxiety disorders, 
male patients 20.6 ± 8.0 ng/ml (n = 
20) and women patients 16.1 ± 6.8 
ng/ml (n = 22). 
GCMS 
Yamauchi et al., 
2001 
Panic disorder patients, 19.3 ± 
8.4 ng/ml (n = 8) 
Generalized anxiety disorder 
patients, 14.4 ± 5.5 ng/ml (n = 10) 
Adjustment disorder patients, 18.4 ± 
9.3 ng/ml (7) 
GCMS 
Reuster et al., 
2002 
12.85 ± 2.02 ng/ml (n = 21), patients 
from a psychiatry department. 
HPLC-ECD 
Hamer et al., 
2006 
Resting MHPG saliva levels of 7.4 ± 
4.6 ng/ml (n = 32) for patients with 
low depressive symptoms and 9.6 ± 
4.7 ng/ml (n = 23) for patients with 
high depressive symptoms. 
GCMS 
Li et al., 2006 
Controls of men and women 
respectively (11.0 ± 5.5 ng/ml, n = 
162 and 10.3 ± 5.5 ng/ml, n = 108).  
GCMS 
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2.9 Analytical method validation 
The objective of validation of an analytical method is to demonstrate that it 
is suitable for i ts intended p urpose. In or der t o dem onstrate t hat t he ne w 
optimised method i s accurate and sp ecific for t he quant ification of  3-
methoxy-4-hydroxyphenylglycol (MHPG) levels in hum an sa liva, th e 
procedures f ollowed f or t he va lidation w ill be descr ibed i n t he f ollowing 
section. 
Chromatographic techniques play a pr edominant r ole i n t he quantitative 
determination of  non -endogenous (drugs and t heir m etabolites) and  
endogenous (naturally occurring) co mpounds in biological samples. 
However, the quantitative determination of endogenous compounds is more 
complicated, analytically and from a validation point of view (Van de Merbel, 
2008). 
In the literature there i s no clear cu t methodology for the va lidation of  the 
quantitative determination of endogenous compounds in biological samples, 
whereas for non -endogenous co mpounds there ar e a few. The  
methodology for va lidation of  a n anal ytical m ethod t hat w as followed a s 
guidance was according t o t he f ollowing docu ments: The Guidance f or 
Industry, B ioanalytical M ethod V alidation of t he Food  and D rug 
Administration (FDA) of the U.S. Department of Health and Human Services 
(FDA, 2001) and the “Bioanalytical method development and validation” by 
Singh and  co -workers (Singh et al ., 20 08), a s well a s chapter 8 on 
Bioanalytical M ethod V alidation in t he book “Analytical M ethod V alidation 
and Instrument Performance Verification” (Garofolo, 2004). 
2.9.1 Method validation parameters 
There ar e a f ew f undamental p arameters for anal ytical m ethod validation 
which include t he f ollowing: se lectivity, se nsitivity, accu racy, pr ecision, 
reproducibility and stability. The va lidation pr ocess also i nvolves 
documenting the performance characteristics of the method to show that it 
is suitable and r eliable f or t he i ntended a nalytical a pplication, and t his is 
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done through the use of specific laboratory investigations. The acceptability 
of the analytical data is ensured by the fact that it corresponds directly with 
the criteria used to validate the method (FDA, 2001). 
The par ameters used t o va lidate t he new  opt imised m ethod, ar e t he 
following. 
2.9.1.1 Specificity / Selectivity 
When a m ethod is specific it means that the method produces a response 
for a singl e analyte only, but when a m ethod is selective i t means that the 
method provides responses for a num ber of  analytes that may or may not 
be di stinguished f rom one another. Selectivity differentiates the anal yte of  
interest from all the other components in a mixture. The ot her components 
do not  n eed t o be  differentiated f rom each  ot her. When a  method i s 
selective it refers to the ability of that analytical method to differentiate and 
quantify the ana lyte or anal ytes of i nterest in t he presences of  ot her 
components in a s ample for ex ample m etabolites, i mpurities, and  
degradants or matrix components.  
The ana lyses of blank samples of the appropriate biological matrix, in this 
case sa liva, a re i mportant fo r selectivity. The bl ank samples sh ould be 
tested for any interference. The lower limit of quantification (LLOQ) must be 
ensured for selectivity. 
In the case of quantitative determination of endogenous compounds it is in 
some cases difficult and s ometimes impossible t o obt ain t he authentic 
biological matrix ( in t his case sa liva) t hat i s free of  t he e ndogenous 
compound ( van de  M erbel, 2008). To so lve t his problem w hen no  
compound free samples of the authentic matrix are available, blank samples 
and calibration standards can be prepared with artificial or surrogate matrix. 
There a re a va riety of su rrogate m atrices available, f or ex ample distilled 
water, a buffer such as artificial cerebrospinal fluid with specific pH (± pH = 
7.4) or  any other solution close  t o t he aut hentic biological m atrix (van d e 
Merbel, 2008). 
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2.9.1.2 Accuracy 
Accuracy describes the close ness of m ean t est results obtained by the 
analytical method to the true value (concentration) of the analyte of interest. 
Accuracy is determined by replicate analysis of samples containing a known 
amount of t he ana lyte. Accuracy is subdivided i nto t he f ollowing 2 
categories, viz. intra-day accuracy and i nter-day accuracy. I ntra-day 
accuracy i s ca lculated by measuring a m inimum o f 5  determinations per 
concentration and a minimum of 3 concentrations in the range of expected 
concentrations is to be use d on t he sa me day . Inter-day accuracy is 
calculated in the same way as intra-day accuracy, but the 5 determinations 
are done on 5 di fferent da ys. The % RSD ( percentage relative st andard 
deviation) of the mean va lue result should be l ess than 15% of the actual 
value except for values at LLOQ, where i t should be less than 20% (FDA, 
2001). The  measurement of  accuracy is expressed in the deviation o f the 
mean from the true value. 
2.9.1.3 Precision (reproducibility) 
Precision describes the closeness of individual measurements of an analyte 
of i nterest when t he analytical procedure i s applied r epeatedly to multiple 
aliquots of a singl e homogeneous volume of  biological matrix. Precision is 
calculated by measuring a minimum of 5 determinations per concentration 
and a minimum of 3 concentrations in the range of expected concentrations 
to be use d. The % RSD determined at each concentration level should be 
less than 15% except f or concentrations at t he LLOQ, where i t should be 
less than 20% (FDA, 2001).  
Precision can be subdivided into following categories: within-run, intra-batch 
precision or repeatability. These categories assess precision during a single 
analytical r un, and bet ween-run, i nterbatch precision or  r epeatability. 
Precision ca n also be measured ove r time, and may involve di fferent 
analysts, equi pment, r eagents, and laboratories. Precision m easures the 
repeatability of the whole analytical procedure, including sample preparation 
under various conditions. 
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2.9.1.4 Lower limit of detection (LLOD) 
The lower limit of  det ection i s the l owest co ncentration of  t he analyte of 
interest that can be d etected in a sample but not necessarily be quantified 
under t he stated ana lytical conditions. I t i s also defined as the l owest 
concentration that can be di stinguished f rom the baseline and background 
noise with a certain degree of confidence.   
2.9.1.5 Lower limit of quantification (LLOQ) 
The lower limit of quantification is the lowest concentration of the analyte of 
interest which can be quant itatively determined with suitable accuracy and 
precision. The LLOQ value is determined by the presence of a baseline or 
background signal  ( accuracy) a nd t he precision of t he anal ytical m ethod 
(reproducibility). The LLOQ should be the lowest concentration value on the 
calibration curve. 
2.9.1.6 Calibration curve / Linearity 
The r elationship be tween an instrument’s response and the known 
concentrations of t he anal yte of i nterest i s expressed i n t he c alibration 
(standard) curve. Each analyte in a sa mple should have its own calibration 
curve. A minimum of  6 co ncentrations (standards) should b e use d t o 
generate a calibration curve covering the expected analytical concentration 
range, including the LLOQ. The standards for the ca libration curve should 
be prepared i n a matrix close t o t he bi ological m atrix of t he endogenou s 
compound.  
The range of standards that is used to construct the calibration curve is a 
function of  the ant icipated range of  analytical values and the nature of  the 
analyte/response r elationship. C oncentrations of the standards should b e 
chosen on  the basis of t he analytical concentration range expected in the 
particular study. The calibration curve data should consist of a blank sample 
(matrix sa mple anal ysed without an i nternal st andard) and  a ze ro sa mple 
(matrix sample analysed with an internal standard). 
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It i s important th at th e calibration ( standard) cu rve should have a l inear 
regression value not  l ess than r 2 = 0. 95, as  this curve w ill be use d t o 
calculate the values of MHPG in the test samples in the study. 
2.9.1.7 Range 
The r ange of  a s pecific analyte f or anal ysis and t he r ange used f or t he 
calibration cu rve is usually t he same. Thi s range i s det ermined by the 
concentrations found of the endogenous compound in a particular biological 
matrix. The lower level (also the LLOQ) must be a co ncentration 10 t imes 
less than the expected lowest endogenous concentration. The upper level 
must be a co ncentration 10 t imes higher t han t he exp ected hi ghest 
endogenous concentration. This i s not al ways possible an d t herefore t he 
range m ust be ch osen in a  w ay t hat m ost of  t he unk nown v alues will f all 
within it. The values of the chosen range are expressed in the same units as 
the test results (e.g. nanogram per  millilitre, percentage, par ts per m illion) 
obtained by the analytical method. 
2.9.1.8 Robustness / Ruggedness 
Robustness measures the a nalyte of  i nterest’s capacity t o r emain 
unaffected by small, but  del iberate va riations in t he anal ytical m ethod’s 
parameters. This will then provide an i ndication of the reliability with which 
the anal yte ca n be  det ermined during nor mal anal ytical u sage. The  
analytical method’s parameters that can be varied are the f low rate of  the 
mobile phase, the pH of the mobile phase, the percentage of the inorganic 
phase in the mobile phase and the column’s temperature. 
2.9.1.9 % Recovery (percentage recovery) 
The % recovery of a  sp ecific a nalyte do es not nee d t o be 1 00%. The % 
recovery of t he anal yte m ust rather be co nsistent, pr ecise and a lso 
reproducible. Experiments to determine % recovery should be done on at 
least 3 co ncentrations (low, m edium and high) of  the st andard r ange and  
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also on t est samples. The % recovery for endogenous compounds can be 
obtained by means of different methods. 
2.9.1.10 Stability 
The stability of the analyte of interest either as standard or as test samples 
is very important.  S tability is a function of  t he sample co llection, storage 
conditions, and chemical pr operties of t he an alyte, th e ma trix, a nd th e 
storage container system. The stability of the analyte should be evaluated 
during sample co llection, a fter short-term storage, long-term storage, after 
being f rozen and following thaw (unfreezing) cycles and also during the 
analytical pr ocess. The stability of t he standard's stock so lution must a lso 
be t ested. The c onditions used i n st ability experiments should r eflect 
situations to be enc ountered du ring act ual sa mple h andling, pr eparation 
and analysis.  
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Research Design & Methodology 
Chapter 
3 
 
As previously stated in chapter 1, was the current study undertaken as part 
of a target popul ation comparative st udy investigating biological m arkers 
e.g. MHPG, associated with higher sympathetic nervous system activity. 
The a im o f t he cu rrent st udy was to dev elop or op timise a m ethod t o 
quantify 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in human saliva. 
HYPOTHESIS 
We anticipate that the new method will be sensitive and specific enough to 
determine 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in human saliva 
samples. 
3.1 Research design 
The r esearch design  w as structured i n or der t o a chieve t he f ollowing 
objectives. 
1. To evaluate the existing method for catecholamine determinations in 
brain tissue in terms of its ability to quantify MHPG in samples. 
2. To optimise the existing method to quantify catecholamines and their 
metabolites in another sample matrix, viz. human saliva. 
3. To validate the new method. 
4. To apply the new method to human saliva samples. 
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3.2 Materials and Instrumentation 
Table 3: Materials and consumables 
Materials & consumables Brand Name 
Polyester salivettes Sarsted 
200 µl Yellow pipette tips Merck 
1000 µl Blue pipette tips Merck 
2 ml amber polypropylene tubes Merck (Eppendorf) 
1.5 ml polypropylene tubes Merck (Eppendorf) 
300 µl Glass inserts Separations 
1.5 ml Amber vails Separations 
Blue nitrile examination gloves Merck 
Table 4: Equipment and instrumentation 
Equipment & 
instrumentation 
Brand Name Location 
Air-Displacement 
Pipettes 
Eppendorf Research ATL 
Volumetric glassware Blue Brand ATL 
Centrifuges Eppendorf & Sigma ATL & LAMB 
Ultra Low Temperature 
Freezer 
New Brunswick Scientific Physiology 
-86°C Cryo Freezer Forma LAMB 
Vortex Gemini ATL 
HPLC 
Agilent 1200 Series: isocratic pump & 
autosampler 
ATL 
Amperometric 
Electrochemical 
Detectors 
GBC LC1260 electrochemical detector & 
ESA Coulochem III electrochemical 
detector 
ATL 
Column Luna C18-2 column, 250 x 4.6 mm, 5 µm Separations 
Data Acquisition & 
Analysis Software on 
Computer connected to 
HPLC-AECD 
Agilent Chemstation Rev.A.06.02 Data 
Acquisition & Analysis Software and 
Chromeleon® Chromatography 
Management System version 6.8 
ATL 
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All t he materials and equipment to be use d are ava ilable in the Analytical 
Technology Laboratory (ATL) and Laboratory for Applied Molecular Biology 
(LAMB) of  t he S chool of  P harmacy at t he N orth-West U niversity, 
Potchefstroom Campus. 
3.3 Methodology 
3.3.1 The existing HPLC electrochemical detection method 
The ana lysis technique which w as optimised i n t his particular st udy is an 
HPLC coupled to an amperometric electrochemical detector method used in 
our department for more than 20 years for quantifying catecholamines and 
their m etabolite levels in br ain tissue, C SF and plasma (Coetzee et al ., 
2006; Harvey et al., 2006; Marais et al., 2006) (see table 5). 
3.3.1.1 Chromatographic conditions 
Table 5: Chromatographic conditions of the existing method 
Analytical Instrument 
Agilent 1100 series HPLC, equipped with 
an isocratic pump, autosampler, GBC LC 
1260 electrochemical detector (with 
amperometric wall jet flow cell, flow cell 
volume is ± 200 µl, glassy carbon target 
electrode and Ag/AgCl reference 
electrode) and Chemstation Rev. A.06.02 
data acquisition and analysis software. 
Column 
Luna C18-2 column, 150 x 4.6 mm, 5 µm, 
100 Å pores, 17.8% carbon load, 
endcapped, Phenomenex, Torrance, CA 
(Column L1, USP 24, 2000, p 1925). 
Guard column 
SecurityGuardTM, HPLC Guard Cartridge 
System, with SecurityGuard Cartridges, 
C18, 4.0 x 3.0 mm, Phenomenex, 
Torrance, CA. 
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Mobile phase 
0.1 M sodium formate buffer, 5 mM sodium 
1-heptanesulfonate, 0.5 mM 
Ethylenediaminetetra- acetic acid disodium 
salt, 6% v/v methanol and 4% v/v 
acetonitrile. The pH of the mobile phase 
was set at ± pH 3.2 with ± 6 ml of 
orthophosphoric acid (H3PO4) (85%). 
Flow rate 1.0 ml/min. 
Injection volume 100 µl 
Amperometric electrochemical 
detector settings 
Settings for the GBC instrument:  Cell 
potential (E): + 600 mV, Range: 5 nA, 
Polarity: Positive, Filter: 64 Point, Filter 
(backside): 0.5 Hz, Reaction: Oxidation, 
Signal output: 1.0 V 
Analog to digital converter 
settings 
Signal 1, Description: AECD, Source: 
Signal Unit: pA (i), Units/Volt: 1000.00, 
Peak width (Data Rate): 0.133 Min (2.00 
Hz), Stop Time: No Limit, Data Storage: All 
3.3.1.2 Reagents 
Solution A (for protein precipitation) 
Contents: 
• 0.5 mM sodium metabisulphite (E Merck, Midrand). 
• 0.3 mM ethylenediaminetetra-acetic acid disodium salt (Na2EDTA) (E 
Merck, Midrand). 
• 0.1 M p erchloric acid ( HClO4) 60% st rong so lution ( E Me rck, 
Midrand). 
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Preparation: 
1. Weigh 0.047525 g sodium metabisulphite and 0.055836 g Na2EDTA 
and dissolve it in 400 ml distilled water. 
2. Add 5. 435 ml per chloric acid t o ab ove s olution a nd m ake up  to 
500 ml with distilled water. 
Note: All standards and internal standard were prepared within this solution 
(Solution A). 
3.3.1.3 Sample preparation of standards and test samples 
1. Following dissection of a br ain from a l aboratory animal (for example a 
rat),  the brain samples were placed i n a  1.5 ml pol ypropylene tube and 
immediately snap f rozen with l iquid ni trogen and st ored in a -80°C f reezer 
until day of analysis.  
2. On the day of analysis the brain samples were weighed and thawed.  
3. 1ml of  so lution A  w as added t o t he t ube.  The br ain t issue was then 
ruptured by sonication. 
4.  The sa mple w as allowed t o st and on ice f or 20 m inutes to co mplete 
perchlorate precipitation of protein and the extraction of the catecholamines. 
5. The sample was then centrifuged at 15300 rpm for 20 minutes at 4°C. 
6. The su pernatant f luid w as removed an d pi petted i nto a 2  ml am ber 
polypropylene tube. 
7. The pH of the sample was adjusted to 5 with the addition of 1drop/ml of 
10 M potassium acetate. 
8. An al iquot of  200  µl of t he sa mple (or st andard) wa s pipetted into a  
1.5 ml polypropylene tube. The rest of the sample was stored at -80°C. 
9. 20 µl of  t he I nternal S tandard ( isoprenaline with co ncentration o f 
1500 ng/ml, made up in solution A) was added. 
10. The final sample was vortexed and then centrifuged at 7 000 rpm for 5 
minutes. 
11. 100 µl of the final sample was injected onto an HPLC column. 
12. The results were expressed in ng/g (nanograms per gram) wet tissue. 
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3.3.2 Optimisation o f th e exi sting HPLC el ectrochemical 
detection method 
The following f actors were taken i nto a ccount dur ing the pr ocess of 
optimising the method (Kromidas, S., 2006). 
1. The composition of the mobile phase. 
2. The pH of the mobile phase. 
3. The analytical column. 
4. The flow rate of the mobile phase through the HPLC system. 
5. The optimal injection volume of the standards and samples. 
6. The sample preparation. 
7. The calibration range for the standards. 
8. The lower limit of detection (LLOD). 
3.3.3 Method validation parameters 
The following validation parameters were followed to validate the new 
method. 
3.3.3.1 Specificity / Selectivity 
Determinations of specificity and se lectivity w ere don e on solution A  and 
artificial cerebrospinal fluid (aCSF, ± pH 7.4) because no compound (in this 
case MHPG) free samples of the authentic matrix (saliva) are available. 
Plasma a nd sa liva were al so used t o ve rify the r esults from t he t wo 
surrogate matrixes, viz. solution A and artificial CSF. 
3.3.3.2 Accuracy 
Intra-day and inter-day accuracy were done on the following three standard 
concentrations: 2.5; 7.5; and 10 ng/ml (as described in 2.9.1.2). 
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3.3.3.3 Precision (reproducibility) 
Precision was done on the following three standard concentrations: 2.5; 7.5; 
and 10 ng/ml (as described in point 2.9.1.3). 
3.3.3.4 Lower limit of detection (LLOD) 
The lower limit of detection for this analytical method is the smallest analyte 
peak detected by the am perometric electrochemical detector and can be 
distinguished from the baseline and background noise with a certain degree 
of confidence.   
3.3.3.5 Lower limit of quantification (LLOQ) 
The lower limit of quantification for this analytical method is the lowest value 
on the calibration curve. 
3.3.3.6 Calibration curve / Linearity 
The calibration curve range that was chosen for this analytical method was 
according t o pr evious l iterature published and a lso according t o pr evious 
results found for MHPG in saliva samples (see references in table 2). 
3.3.3.7 Range 
The r ange of M HPG co ncentrations that w as chosen f or t his analytical 
method is the same as for the calibration curve mentioned in 3.3.3.6 above. 
3.3.3.8 Robustness / Ruggedness 
The parameters that were changed to test for robustness were the flow rate 
of t he m obile p hase, the pH  of  the m obile phase , t he per centage of  t he 
inorganic phase in the mobile phase, the column’s temperature or the room 
temperature. 
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3.3.3.9 % Recovery (percentage recovery) 
% Recovery was determined for the analyte (MHPG) out of the salivette as 
well as for the complete method. For % recovery from the salivette, only the 
standards were used. 
Table 6: % Recovery from the salivette 
Samples analysed for % Recovery 
A standard sample Sample A 
A standard sample that was put through a salivette Sample B 
The following equation was used to calculate the % recovery. 
 
The answer has to be close to 100% but not less than 80%. 
To determine the % recovery for the analyte (MHPG) for the completed new 
method, standards and test saliva samples were used. 
Table 7: % Recovery for MHPG for the complete new method 
Samples analysed for % Recovery 
Blank aCSF sample +   
Blank  aCSF sample + 
Spiked with known 
concentration MHPG 
Sample A 
Standard or test sample +  Sample B 
Standard or test sample + 
Spiked with known 
concentration MHPG 
Sample C 
The blank sample should be in a matrix close to the test sample for example 
saline or artificial CSF. 
The %  recovery for t he kn own spiked c oncentration was determined by 
means of the following equation: 
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The answer has to be close to 100 % but not less than 80 %. 
3.3.3.10 Stability 
The stability of M HPG w as tested f or und er the f ollowing c onditions: the 
stock solution for the standards was tested for long term stability at -80°C. 
The st andards used for t he ca libration cu rve and l inearity were tested f or 
long term stability at -20°C, freeze and t haw (unfreezing) stability and also 
stability in the autosampler at room temperature (18-24°C) over 24 hours. 
3.3.4 Application of new optimised method to human saliva 
samples and data analysis 
This new optimised HPLC electrochemical detection method was applied to 
human sa liva sa mples from t he S ABPA pr oject t o quantify MHPG 
concentration levels. 
The human saliva samples were prepared according to the new method’s 
sample pr eparation, w here-after t he prepared sa mples were analyzed o n 
the HPLC amperometric electrochemical detector system. 
The MHPG peak area data of each  hum an sa liva sample with it s internal 
standards peak area data were used to calculate the MHPG concentration 
of each human saliva sample.  
The results were calculated according to the calibration curve’s straight line 
equation and expressed in ng/ml (nanograms per millilitre). 
While this study was focussed on method deve lopment and va lidation, no 
statistical analysis of human sample data was preformed. 
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Results & Discussions 
Chapter 
4 
 
4.1 The New Optimised HPLC Amperometric 
Electrochemical Detection Method 
The factors mentioned in 3.3.2 were taken into account and changed in the 
process to optimise t he existing method (see 3.3.1) in or der t o anal yse 
MHPG successfully. 
 4.1.1 Chromatographic conditions 
Table 8: Chromatographic conditions of the new method 
Analytical instrument: 
Instrument 1 used 
Agilent 1200 series HPLC, equipped 
with an isocratic pump, autosampler, 
coupled to a GBC LC 1260 
Electrochemical detector (with 
amperometric wall jet flow cell, flow 
cell volume is ± 200 µl, glassy 
carbon target electrode and Ag/AgCl 
reference electrode) and 
Chemstation Rev. A.06.02 data 
acquisition and analysis software. 
Analytical instrument: 
Instrument 2 used 
Agilent 1200 series HPLC, equipped 
with an isocratic pump, autosampler, 
coupled to an ESA Coulochem III 
Electrochemical detector (with thin 
layer amperometric flow cell, flow 
cell volume is ± 10.5 µl, glassy 
carbon/ceramic target electrode) and 
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Chromeleon® Chromatography 
Management System version 6.8. 
Column 
Luna C18-2 column, 250 x 4.6 mm, 
5 µm, 100 Å pores, 17.8% carbon 
load, endcapped, Phenomenex, 
Torrance, CA (Column L1, USP 24, 
2000, p 1925). 
Guard column 
SecurityGuardTM, HPLC Guard 
Cartridge System, with 
SecurityGuard Cartridges, C18, 4.0 x 
3.0 mm, Phenomenex, Torrance, 
CA. 
Mobile phase 
0.1 M Sodium formate buffer 
(6,801 g/l), 5 mM Sodium 1-
heptanesulfonate (1,01125 g/l), 
0.17 mM Ethylenediaminetetra- 
acetic acid disodium salt (20 mg/l), 
4% v/v acetonitrile. The pH of the 
mobile phase was set at ± pH 4.1 
with orthophosphoric acid (H3PO4) 
(85%). 
Flow rate 0.85 ml/min 
Injection volume for instrument 1 10 µl (flow cell volume = ± 200 µl) 
Injection volume for instrument 2 5 µl (flow cell volume = 10.5 µl) 
Amperometric electrochemical 
detector settings for instrument 1 
Settings for the GBC instrument: Cell 
potential (E): + 750 mV, Range: 
200 pA, Polarity: Positive, Filter: 64 
Point, Filter (backside): 0.5 Hz, 
Reaction: Oxidation, Signal output: 
1.0 V. 
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Amperometric electrochemical 
detector settings for instrument 2 
Settings for the ESA Coulochem III 
instrument: Cell potential (E): + 
750 mV, Range: 200 pA, Filter: 0.5 
sec, Offset: 0%, Signal output: 1.0 V. 
Analog to digital converter 
settings for the GBC instrument 
Signal 1, Description: AECD, 
Source: Signal, Unit: pA (i), 
Units/Volt: 1000.00, Peak width 
(Data Rate): 0.133 Min (2.00 Hz), 
Stop Time: No Limit, Data Storage: 
All. 
Relative retention times 
3-Methoxy-4-hydroxyphenylglycol 
(MHPG) ± 9 minutes. 
3,4-Dihydroxy-benzylamine (DHBA) - 
Internal Standard ± 24 minutes. 
4.1.2 Reagents 
Solution A 
Contents: 
• 0.5 mM sodium metabisulphite (E Merck, Midrand). 
• 0.3 mM ethylenediaminetetra-acetic acid disodium salt (Na2EDTA) (E 
Merck, Midrand). 
• 0.1 M per chloric acid ( HClO4) 60%  st rong so lution ( E Me rck, 
Midrand). 
Preparation: 
1. Weigh 0.047525 g sodium metabisulphite and 0.055836 g Na2EDTA 
and dissolve it in 400 ml distilled water. 
2. Add 5. 435 ml per chloric acid t o ab ove s olution a nd m ake up t o 
500 ml with distilled water. 
3. Note: All standards were prepared in this solution (solution A). 
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Solution C (Inhibitor solution) 
This solution w as used by Okumura and co -workers to st abilize 
catecholamines in saliva samples (Okumura et al., 1997). 
Contents: 
• 0.3 mM e thylene g lycol-bis(β-aminoethylether)-N,N’,N’-tetraacetic 
acid (EGTA) (Sigma- Aldrich, Aston Manor). 
• 0.5 mM L-glutathione reduced form (Sigma- Aldrich, Aston Manor). 
• 0.1 M h ydrochloric acid ( HCl) 32%  st rong so lution ( E Me rck, 
Midrand). 
Preparation: 
Weigh 0.011412 g EGTA and 0 .0153665 g L-glutathione and d issolve i t in 
80 ml distilled water. Add 984 µl of HCl and make up w ith distilled water to 
100 ml. The EGTA and L-glutathione was used to stabilize MHPG in saliva 
samples. 
4.1.3 Preparation of standard solutions 
3-Methoxy-4-hydroxyphenylglycol hemipiperazinium sa lt = 45 4.5 M W 
(Sigma- Aldrich, Aston Manor). 
3-Methoxy-4-hydroxyphenylglycol (MHPG) = 184.19 MW (40.50%) 
Weigh 1.23 mg and dissolve it in 10 ml of solution A, 40.50% of the 1.23 mg 
will be 0 .5 mg that w ill r epresent 3-methoxy-4-hydroxyphenylglycol (Gupta 
et al., 1987). 
This solution w ill be the st ock solution ( SS) f or al l t he st andards and will 
have a concentration of 50 µg/ml.  
All of  t he working standards will be prepared f rom this solution, see t able 
below. 
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Table 9: Preparation of standard solutions 
Working Concentration + Dilution = Solution A Total 
(ng/ml) Standards     Volume 
              
1 1 20 µl (B) + 1980 µl = 2 ml 
       
2 2.5 50 µl (B) + 1950 µl = 2 ml 
       
3 5 100 µl (B) + 1900 µl = 2 ml 
       
4 7.5 150 µl (B) + 1850 µl = 2 ml 
       
5 10 200 µl (B) + 1800 µl = 2 ml 
       
6 15 300 µl (B) + 1700 µl = 2 ml 
       
7 20 400 µl (B) + 1600 µl = 2 ml 
       
B 100 ng/ml 200 µl (A) + 9800 µl = 10 ml 
       
A 5 µg/ml 200 µl (SS) + 1800 µl = 2 ml 
 
4.1.4 Preparation of internal standard (I. Std) 
3,4-Dihydroxy-benzylamine ( DHBA) =  220. 1 M W (Sigma- Aldrich, Ast on 
Manor) 
Weigh off 1 mg and dissolve it in 10 ml of solution A, this solution will be the 
stock solution for the internal standard. Take 50 µl of the stock solution and 
make up to 10 ml with a 0.25 M perchloric acid solution, this solution will be 
the w orking i nternal st andard so lution. The f inal concentration of  t he 
working internal standard solution will be 500 ng/ml. 
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4.1.5 Sample preparation of standards and test samples 
1. The collected sa liva samples were immediately snap f rozen with l iquid 
nitrogen and stored in a -80°C freezer until day of analysis. 
2. On t he d ay of anal ysis the s alivettes with sa liva samples will b e 
removed from the -80°C freezer to thaw (to unfreeze) on ice. 
3. Add 15 µl of solution C to the bottom part of the salivette. 
4. The samples were centrifuged at 5500 rpm (5445 gs) for 35 minutes at 
4°C to ensure that all the saliva is drained out of the cotton roll. 
5. All the saliva was transferred to 2ml amber polypropylene tube. 
6. 100 µl of  a standard or  a saliva Sa mple was pipetted into a 1. 5 ml 
polypropylene tube. The rest of the saliva sample was stored at -80°C. 
7. Add 1 5 µl of t he internal s tandard ( DHBA with co ncentration o f 
500 ng/ml), made up i n 0.25 M perchloric acid solution. The reason for the 
0.25 M perchloric acid is to precipitate any proteins in the sample. 
8. Mix the sample with a vortex and centrifuge at 15300 rpm (21460 gs) for 
15 minutes. 
9. The whole sample was pipetted into a 300 µl glass insert, which fits into 
an amber glass vial which is placed into the sample tray of the Agilent 1200 
series autosampler. 
10. The instrument’s software was programmed to inject 5 µl of the sample 
onto the column. 
11. The software will collect the data. 
12. The peak area data of each sample were typed in to a M icrosoft Excel 
spreadsheet to be processed. 
13. The results were expressed in ng/ml (nanograms per millilitre). 
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4.2 Chromatographic results 
The f ollowing typical chromatographic results are ex amples of a bl ank 
solution A  sa mple (figure 8) , a bl ank artificial cerebrospinal fluid ( aCSF) 
sample (figure 9), a blank aCSF sample spiked with a known concentration 
of MHPG (figure 10), 2 standard MHPG samples (figures 11 & 12), a pooled 
saliva s ample (figure 13) , a po oled p lasma sa mple (figure 14) , a sa liva 
sample (figure 15) and a spiked saliva sample (figure 16). 
The standard samples runtime on the HPLC was only 30 m inutes long, but 
the sa liva samples was 50 m inutes long because of  unkn own peaks that 
eluted later than 30 minutes.  
 
Figure 8:  C hromatogram of  a bl ank solution A s ample with i nternal 
standard. 
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Figure 9: Chromatogram of a blank aCSF sample with internal standard. 
 
Figure 1 0: Chromatogram of a bl ank aCSF sample spiked w ith 5 µl of  a 
500 ng/ml MHPG with final MHPG concentration of 25 ng/ml. 
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Figure 11 : C hromatogram of  a  2. 5 ng/ml M HPG s tandard sample (in 
solution A). 
 
Figure 12: Chromatogram of a 10 ng/ml MHPG standard sample (in aCSF). 
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Figure 13: Chromatogram of a pooled saliva sample. 
 
Figure 14: Chromatogram of a pooled plasma sample. 
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Figure 15: Chromatogram of a saliva sample with a MHPG concentration of 
25.88 ng/ml. 
 
Figure 16 : Chromatogram of  t he same sa liva sample as figure 14, sp iked 
with 5  µl of a 500 ng/ml M HPG, with a f inal M HPG co ncentration of  a 
46.51 ng/ml. 
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4.3 Validation results 
4.3.1 Specificity / Selectivity 
This new optimised method could detect MHPG in all the matrices (solution 
A, a rtificial ce rebrospinal f luid, plasma an d saliva samples) without any  
interference (see figures 8 to 16). 
 
4.3.2 Accuracy and precision 
Table 10: Accuracy and precision 
Accuracy & 
precision 
Validation 
Samples 
Concentration 
added (ng/ml) 
Mean concentration 
found (ng/ml) 
RSD 
(%) 
Accuracy 
(%) 
n 
Intra-day 2.5 2.5 3.11 12.67 124.40 5 
 
7.5 7.5 8.10 3.07 108.00 5 
 
10.0 10.0 10.19 4.93 101.90 5 
Inter-day 2.5 2.5 2.77 6.77 110.80 5 
 
7.5 7.5 7.63 10.23 101.73 5 
 
10.0 10.0 10.58 4.86 105.80 5 
 
4.3.3 Lower limit of detection (LLOD) 
The lower limit of detection was found to be 1.0 ng/ml. 
 
4.3.4 Lower limit of quantification (LLOQ) 
The lower limit of quantification was found to be 2. 5 ng/ml, which was also 
the lowest concentration on the calibration curve. 
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4.3.5 Calibration curve / Linearity 
The ca libration cu rve used i n t his validation pr ocess comprised of  the 
following c oncentrations: 2. 5, 5. 0, 7. 5, 10. 0, 15. 0, and 20. 0 ng/ml. Each 
standard was analysed in triplicate. 
The ca libration gr aph w as pl otted using  t he peak  area of  t he M HPG 
standards divided by  the peak area of  that sp ecific standard’s internal 
standard. 
Table 11: Data of the calibration curve 
Calibration curve data 
MHPG 
          
Standards Standards Internal standard Standard / Internal standard 
Conc. Peak area 
1 2 3 Avg. 
ng/ml 1 2 3 1 2 3 
2.5 1185 1128 1374 9302 10368 10794 0.127 0.109 0.127 0.121 
5 1656 1680 2053 9611 10896 10649 0.172 0.154 0.193 0.173 
7.5 2128 2269 2748 8854 10267 9842 0.240 0.221 0.279 0.247 
10 3086 3300 3407 9646 12217 10308 0.320 0.270 0.331 0.307 
15 3858 4212 4268 8838 10402 10339 0.437 0.405 0.413 0.418 
20 5384 5587 5343 8997 11226 11036 0.598 0.498 0.484 0.527 
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Figure 17: Calibration curve (Linearity curve). 
The l inearity value of  the calibration curve was good ( r2 = 0.998) and w as 
better than the criteria set for it.  
The equation for the straight line was y = 0.0234x + 0.0651. 
 
4.3.6 Range 
The r ange ch osen a nd use d f or this study was from 2 .5 to  2 0.0 ng/ml a 
range that correlates with the values usually found in saliva. 
  
4.3.7 Robustness / Ruggedness 
The new method w as found t o be r obust. The p arameters t hat w ere 
changed t o t est f or robustness did not  h ave any notable effects on t he 
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chromatogram or t he MHPG peak. Ther e was only a sli ght change i n t he 
retention time of the MHPG. The size and the shape of the peak stayed the 
same each time. 
 
4.3.8 % Recovery 
Table 12: Results of % recovery of MHPG out of the salivette: 
MHPG standard sample % Recovery 
1 ng/ml (LLOD) 98.96 
2.5 ng/ml (LLOQ) 99.09 
5.0 ng/ml 94.46 
7.5 ng/ml 88.44 
10.0 ng/ml 85.83 
15.0 ng/ml 91.22 
  
Table 13:  % Recovery r esults f or MHPG f ollowing t he whole 
methodological procedure: 
Samples that was spiked with a known 
concentration of MHPG (5µl of 500ng/ml) (n = 2) 
% Recovery 
2.5 ng/ml (LLOQ) 104.99 
7.5 ng/ml 92.65 
10.0 ng/ml 109.18 
15.0 ng/ml 83.36 
Saliva sample 1 91.41 
Saliva sample 2 81.57 
Saliva sample 3 88.89 
Saliva sample 4 91.95 
Saliva sample 5 91.25 
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4.3.9 Stability 
The MHPG stock solution as well as standard samples prepared f rom the 
stock solution tested for long term stability at -80°C was found to be 100% 
stable for at least a month.  
The standard samples that were used for the calibration curve and l inearity 
that was tested for long term stability at -20°C was found to be 100% stable 
for at least a month. 
The standard samples were found to be 100 % stable af ter the freeze and 
thaw (unfreezing) processes.  
The standard samples were found to 100% stable when left for a 24 hou r 
period in the autosampler, at room temperature (18-24°C). 
4.4 Application to human saliva samples 
The MHPG co ncentrations obtained in t he human saliva s amples were 
between the ranges of 3 ng/ml to 20 ng/ml. 
Table 14: Results from human saliva samples 
Quantification of MHPG Peaks in human Saliva Samples 
Human saliva 
samples 
MHPG 
peak area 
I. Std   
peak area 
MHPG/I. Std 
peak area 
Calculated 
concentration in 
ng/ml 
(y=0.0234x+0.0561) 
Patient 1 43451.37 296839.85 0.146379826 3.86 
Patient 2 42533.71 230609.46 0.184440452 5.48 
Patient 3 67655.41 280270.18 0.241393532 7.92 
Patient 4 91905.81 274794.15 0.334453276 11.89 
Patient 5 124453.61 247785.93 0.502262602 19.07 
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The f ollowing ch romatograms of t he hum an sa liva s amples analysed ar e 
typical examples of what was found throughout the study. 
 
Figure 18 : C hromatogram of  a  hum an sa liva sa mple with a M HPG 
concentration of 3.85 ng/ml (Patient 1). 
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Figure 19: Chromatogram of a hum an saliva sample (MHPG = 5.48 ng/ml, 
Patient 2). 
 
Figure 20: Chromatogram of a hum an saliva sample (MHPG = 7.91 ng/ml, 
Patient 3). 
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Figure 21: Chromatogram of a human saliva sample (MHPG = 11.89 ng/ml, 
Patient 4). 
 
Figure 22: Chromatogram of a human saliva sample (MHPG = 19.06 ng/ml, 
Patient 5). 
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4.5 Discussion 
4.5.1 The n ew o ptimised HP LC amperometric 
electrochemical detection method 
4.5.1.1 The composition of the mobile phase 
The composition of the mobile phase stayed more or less the same as the 
one used in the existing method, except that the organic part was changed 
from 10% methanol/acetonitrile mixture to only 4% acetonitrile. The pH was 
made a little less acidic and was changed from pH 3.2 to pH 4.1. Both these 
changes were necessary because the MHPG peak elutes very fast due to 
its molecular characteristics.   
4.5.1.2 The column 
The co lumn's length use d i n t he optimised method w as changed f orm 
150 mm to 250 mm. This change was also necessary due to the fast elution 
of the MHPG’s peak. 
4.5.1.3 The flow rate 
The flow rate was changed from 1.0 ml/min to 0.85 ml/min, the slower flow 
rate also decreased the speed of elution of MHPG's peak. 
4.5.1.4 The optimal injection volume 
The i njection vo lume w as changed f rom 100  µl t o 10 µl for t he G BC 
instrument and to 5  µl for the Coulochem I II instrument. This change from 
10 µl t o 5  µl was because t his instrument’s flow ce ll is much smaller t han 
that of the GBC electrochemical detector. 
4.5.1.5 The cell potential setting of the electrochemical detector 
The cell potential ( in m illivolt) se tting of  t he el ectrochemical det ector w as 
changed f rom +600mV to +750mV. This setting was used because i t was 
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found to be the most sensitive setting for the MHPG molecule, being more 
electrically conductive at +750mV than at +600mV. The MHPG peak on the 
chromatogram w as also gr eater i n s ize at t his new setting t han at the 
previous one. 
4.5.1.6 The sample preparation 
The s ample pr eparation di ffered a considerably from the or iginal m ethod 
because saliva is a fluid and br ain tissue is solid. Solution C was added to 
the sa liva to st abilize t he sa mple and t o neutralize any enzymes in t he 
saliva sa mple. The i nternal st andard so lution w as added t o t he sa liva 
sample not  onl y to a dd t he i nternal st andard but  al so t o precipitate an y 
proteins in the sample. This was done to ensure that t he sample i s clean 
from any proteins that can harm the HPLC column by clogging it. 
4.5.1.7 The calibration range for the standards 
The calibration range for MHPG in sa liva was chosen according to results 
found in literature (see table 3). 
4.5.1.8 The l ower l imit of  d etection ( LLOD) and l ower l imit of  
quantification (LLOQ) 
The l ower limit of  det ection f or t he opt imised method w as found t o be 1 
ng/ml and the lower limit of quantification was 2.5 ng/ml. 
 4.5.1.9 The validation of the method 
The optimised method was found to be sensitive and selective for MHPG in 
all the m atrixes it w as analysed (see f igures 8 t o 16 and 18  to 22) . The 
accuracy and pr ecision gave  percentage r elative st andard deviat ion ( % 
RSD) va lues, al l less than 15%, that were within the criteria set for i t (see 
points 2.8.1.2 and 2. 8.1.3). The ca libration cu rves (linearity) gave  a 
regression value (r2 = 0.998) that was very good. The method was found to 
be robust. The percentage recovery results were also good, all above 80%, 
which is good f or t he anal ysis of  endog enous compounds in bi ological 
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samples. The st ability of MHPG has met all the requirements that were set 
for it (see point 4.3.9). 
4.5.1.10 Application of the method to human saliva samples 
The M HPG co ncentrations obtained with t he opt imised method appl ied t o 
human sa liva sa mples, correlated w ell w ith t he r ange of  M HPG va lues 
found in the literature (see table 3) with values between 7 ng/ml to 20 ng/ml. 
While t he f ive hum an sa mples taken f rom t he S ABPA pr oject w ere 
representative of both baseline and following a stress procedure, the MHPG 
values ranged also from low to high. This is not an unexpected finding for a 
study like this (SABPA – Appendix B). 
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Conclusions & 
Recommendations 
Chapter 
5 
 
5.1 Conclusions 
The aim of the current study was to develop or optimise an exist ing HPLC-
ECD method to quantify 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in 
human saliva. This aim was achieved by the study, as we were able to: 
• Optimise an exist ing HPLC-ECD method f or t he quant ification of 
catecholamines and t heir metabolites in r at brain t issue t o be used 
for the quantification of 3-methoxy-4-hydroxyphenylglycol (MHPG) in 
human saliva. 
• Validate the optimised method in our laboratory and showed it to be 
selective a nd s ensitive f or M HPG in  sa liva g iving reproducible a nd 
repeatable results. 
• Apply this optimised method to samples of human saliva and found 
that the MHPG levels quantified by this method correlated extremely 
well with the values reported in literature. 
Finally the new opt imised H PLC amperometric electrochemical det ection 
method may be used i n f uture studies t o quant ify MHPG in human saliva 
samples. 
5.2 Recommendations 
There are a few recommendations to be made for future studies.  
• A f ilter in the salivette, between the insert vessel and the centrifuge 
tube m ay help t o f ilter out  any  i mpurities and proteins, t hereby 
obtaining a cleaner sample. The samples can be put  through a so lid 
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phase e xtraction pr ocedure but  t his will make t he method m ore 
expensive. 
• Identification of the rest of the unknown peaks in the saliva samples 
may broaden t he r ange of  end ogenous co mpounds t hat m ay be 
analysed through this method. 
• In order to increase the sensitivity and selectivity of the method even 
more, t he amperometric electrochemical de tector can be r eplaced 
with a  c oulometric el ectrochemical detector or  a co ularray 
electrochemical detector. 
• It may be of value to investigate ways in which a shorter runtime can 
be achieved (e.g. other mobile phase or column). 
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Appendix A 
High performance liquid chromatography electrochemical 
detection troubleshooting 
The following table gives a summary of all the most general troubleshooting 
an an alyst w ill co me acr oss when w orking w ith an  HPLC co upled t o an  
electrochemical detector (ESA, Inc., 2004; GBC Scientific Equipment PTY, 
1995). 
Problem Possible Cause Solution 
Baseline drift 
Electrochemical detector not 
equilibrated 
Wait until detector is 
equilibrated; stable 
baseline. 
 
HPLC column not properly 
equilibrated 
Properly equilibrate HPLC 
column 
 
Variation on in mobile phase 
flow 
Check HPLC pump 
 Reference electrode worn 
Replace reference 
electrode 
 Fluctuation in temperature 
Make sure room 
temperature stays stable 
Noisy 
baseline and 
Very fast 
noise spikes 
Flowcell has air bubble 
Remove bubble through 
flushing; make sure mobile 
phase is thoroughly 
degassed. 
 Poor working electrode 
Replace or repolish the 
working electrode’s surface 
 Reference electrode worn 
Replace reference 
electrode 
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Problem Possible Cause Solution 
Output signal 
constantly 
pegged at the 
maximum 
level 
Poor working electrode 
Replace or repolish the 
working electrode’s surface 
 Reference electrode worn 
Replace reference 
electrode 
High 
Background 
current 
HPLC water quality is poor 
Use freshly prepared 
HPLC water 
 Reagents quality is poor Use highest purity reagents 
 
Electro-active material slowly 
eluting from column 
Replace or clean column 
Gradual 
loss/decrease 
in signal 
response 
Fouling working electrode 
Repolish or the working 
electrode’s surface 
 Reference electrode worn 
Replace reference 
electrode 
 Sample unstable Use a fresh sample 
 Change in mobile phase pH 
Check mobile phase pH 
and adjust or freshly 
prepare new mobile phase 
 
Change in mobile phase 
composition 
Check mobile phase and 
prepare fresh mobile phase 
 
Accidental change of a 
parameter on the recorder or 
detector 
Check parameter settings 
and correct setting 
 
Compounds of interest starting 
to decompose  
Prepare fresh standards 
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Problem Possible Cause Solution 
Changes in 
retention 
times of 
compounds of 
interest 
HPLC column not properly 
equilibrated 
Properly equilibrate HPLC 
column 
 Fluctuation in temperature 
Make sure room 
temperature stays stable 
 Change in mobile phase pH 
Check mobile phase pH 
and adjust or freshly 
prepare new mobile phase 
 
Change in mobile phase 
composition 
Check mobile phase and 
prepare fresh mobile phase 
 Flowrate setting not correct Set flowrate correct  
Back pressure 
increases 
Clogged injector or column or 
guard column 
Clean injector, clean or 
replace column, replace 
guard column 
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Appendix B 
NORTH-WEST UNIVERSITY 
POTCHEFSTROOM CAMPUS 
SCHOOL FOR PHYSIOLOGY, NUTRITION AND CONSUMER SCIENCES 
 
The SABPA Project (Sympathetic activity and Ambulatory Blood 
Pressure in Africans) 
 
PARTICIPANT INFORMATION AND CONSENT FORM 
 
PART 1 
 
PRINCIPAL RESEARCHER: Dr Leoné Malan, Subject Group Physiology  
 
PROJECT LEADER: Dr Leoné Malan, Subject Group Physiology  
 
Associate Researcher(s): The pos tdoctoral fel low involved in this tr ial i s Dr. P  
Szabolcs. O ther per sons as sisting i n the s tudy ar e D r. H ugo W. H uisman, P rof. 
Johannes M. van Rooyen, Prof. Nico T. M alan, Mrs. Carla M.T. Fourie, Mrs. Tina 
Scholtz ( Cardiovascular r esearch gr oup, P hysiology), P rof. S alomé K ruger &  D r. 
Ramoteme Mamabolo, (Physical activity), Proff. Hans de R idder (Anthropometry), 
Marié Wissing (Psychology), Linda Brand & Brian Harvey (Pharmacology), Kobus 
Mentz ( Education), Fr ancois v an der  Wes thuizen ( Biochemistry), H ester K lopper 
(Nursing), N ancy Fr asure-Smith &  Fr ancois L espérance ( Psychology, C anada), 
Alaa A lkerwi ( Epidemiology, Lux embourg), Yackoob S eedat ( ECG, K wazulu 
Natal), Paul Rheeder (Sonar, Pretoria Univeristy), Drs. Johan Potgieter & Michael 
Temane & Mr Thumi Khumalo (Psychology), Mrs Gedina de Wet (Nursing). 
 
This Participant Information and Consent Form is 8 pages long. Please make sure 
you have all the pages. 
  
Your Consent 
 
You are invited to take part voluntarily in this research project.  
This par ticipant i nformation document contains detailed information about the 
research project which has been explained to you verbally. Its purpose is to explain 
to you as openly and clearly as possible all the procedures involved in this project 
before you decide whether or not to take part.  
Please read this Participant Information Form carefully. Feel free to ask questions 
about any information in the document. You may also wish to discuss the project 
with a relative or friend or your local health worker. Feel free to do this. 
Once you understand what the pr oject is about and i f you agree to tak e part in it, 
you w ill be asked to s ign the C onsent For m. By s igning the C onsent For m, you 
indicate that y ou under stand the i nformation and that y ou gi ve y our c onsent to 
participate in the research project. 
You will be given a copy of the P articipant Information and Consent Form to keep 
as a record. 
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What is the study about? 
 
The aim of this project is to have an impact on the eventual prevention and 
treatment o f l ifestyle di seases i n Africans fr om S outh A frica. N ew k nowledge 
regarding t he r elationship betw een hi gher n ervous s ystem ac tivity implicating 
cardiovascular, metabolic and psychological well-being will improve understanding 
and c hange s trategies at the r oots of tr eatment and prevention of l ifestyle 
diseases.  
Our r esearch has  s hown that l ifestyle di seases i n ur banised Africans pr esent 
higher obes ity l evels, high bl ood pr essure or  h ypertension pr evalence r ates and  
the ex periencing of m ore s tress. This patter n i s enhanc ed dur ing ps ychosocial 
stress/urbanisation in participants with a specific coping style. Hence the planned 
SABPA pr oject, w hich i s the fi rst s tudy i n S outh A frica where c oping and di rect 
markers of nervous system activity in Africans will be measured.  
 
Purpose of study 
 
The purpose of thi s s tudy i s to i nvestigate bi ological m arkers as sociated w ith 
higher s ympathetic nervous s ystem ac tivity i n ur banised t eachers w ith a s pecific 
coping style.  
To i nvestigate the r elationship bet ween bl ood pr essure, i nflammation, obes ity, 
stress and coping in more detail we are going to perform this study in 400 men and 
women from the N orth-West pr ovince, aged  2 5-60 y ears. A  comprehensive 
assessment of the cardiovascular and nervous systems by means of non-invasive 
painless techniques will be performed and a blood sample will be taken by an 
experienced r esearch doc tor and nur se to deter mine y our b lood s ugar, 
cardiovascular, inflammation and s tress hor mone l evels am ongst other  heal th 
markers.  
 
Procedures 
 
All measurements are performed in the Metabolic Unit (lipid clinic) of the 
University. A researcher has explained the entire procedure in detail and while you 
are reading this information document you have time to ask questions and to have 
clarified matters. If you are fine with the explained procedure you are requested to 
sign a *consent form (at the end of this document). Remember all personal data 
will be handled with care and remain confidential.  
*By c onsenting to par ticipate i n thi s s tudy, y ou consent to t he s torage and l ater 
analysis and testing of your s tored blood samples for  the purposes noted above. 
Your blood will also be tested for preliminary results on HIV status, since your HIV 
status may directly influence the main purposes of this study. If you would l ike to 
know what your HIV-status is, we will provide it. If tested positive we will refer you 
to your doctor and he/she will perform the necessary tests which will allow you to 
apply for chronic medication benefit. Also, the blood cells from your donated blood 
sample will be used to investigate the molecular genetics of higher nervous system 
activity and  ty pe 2  diabetes in or der to ena ble pr e-symptomatic diagnosis of  
hypertension and diabetes in the long term.  
 
 
Why was I chosen?  
 
Teachers are exposed to changing curricula and disciplinary problems whilst living 
in an ur banised env ironment addi ng to hi gher s tress ex periencing and ner vous 
system activity.  
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How was I chosen? 
 
Inclusion criteria:  
Phase I: 200 black Africans aged 25-60 years (male=100, female = 100) 
Phase II: 200 white Africans (n = male, 100 = female) aged 25-60 years. 
 
Exclusion c riteria: pregnancy, l actation, any acute/chronic m edication ( e.g. high 
blood pr essure, TB /tuberculosis, hi gh s ugar/diabetes, arthritis, anti -clotting/stroke 
factors, epilepsy/mental diseases or being treated for  i t as well being addicted to 
the medicine). You can not be included if you have been vaccinated in the previous 
3 months and if you are a regular blood donor. 
 
What will be expected of me? 
 
You, as  par ticipant w ill be s creened onc e by  a r egistered nur se to be el igible 
complying to the inclusion criteria. The following procedures will be followed: 
o Recruitment, screening and informed sessions with all participants will be done 
two months prior to the study (October - November 2007, Phase I, and November, 
2008, Phase II) and informed consent forms will be signed.  
o After s election of al l pa rticipants, th e detai ls of  the pr oject w ill be di scussed 
with you in English or  your home language, i .e. what the e xact objectives of the  
study are, what procedures will be t aken and what will be e xpected from each of 
you (e.g. overnight stay, resting blood pressure procedures and fas ting urine and 
blood s amples ar e r equired, i mportance of c omplying w ith the c orrect s ampling 
methods, incentives). You will be given the opportunity to ask questions.  
o Data collection for each participant will involve two days (15min in the morning 
and 2½ hours in the evening) on Day I; and 2 hours on Day II): 
 
DAY I  
o On day  I at  0 7:00, the bl ood pr essure appar atus, w hich w ill m easure y our 
blood pr essure and he art func tion as w ell as  a phy sical ac tivity m eter w ill b e 
applied to your arm and waist at your school and you can then resume your normal 
daily activities. In the after noon you must complete the Neethling Brain Instrument 
questionnaire which measures thought processes of the brain. 
o At the end of D ay I ( ± 16:30) y ou w ill be tr ansported fr om y our s chools to  
overnight in the Metabolic Unit Research Facility of the North-West University. This 
unit i s a r esearch uni t for  hum an s tudies an d equi pped w ith 10 w ell fur nished 
bedrooms, a k itchen, tw o bathr ooms and a  t elevision r oom. E ach o f y ou will b e 
subjected to the following procedures: 
 At the end of D ay I between ± 17:15 and 18:00 y ou will be welcomed and 
each of you will receive your own private bedroom. 
 The procedures, which will be done, will be ex plained again and eac h of 
you w ill th en c omplete a gener al s ocio-demographic heal th que stionnaire. 
Afterwards you will receive dinner.   
 After di nner, ps ychological ques tionnaires w ill be c ompleted under  
supervision of registered education s pecialists and psychologists. Completion of 
questionnaires will take approximately 40 min, including a break of 20 minutes with 
coffee/tea and biscuits. This willl be you last meal for Day I as you must be fasting 
on Day II for obtaining good results. 
 Thereafter, y ou c an r elax and w atch tel evision or  s ocialise w ith y our c -
participants. It will be wise to go to bed not later than 22:00 as the blood pressure 
apparatus will take measurements every hour during the night and it can be tiring.  
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DAY II 
 
 At 06:45 o n D ay II th e A MBP will be r emoved and an urine s ample 
collected. O nce thi s ha s been don e y ou w ill be di rected to the ant hropometric 
station where your weight, height and body circumferences will be measured.  
 The next station involves the blood pressure measurement station. Whilst 
in a sitting position your blood pressure will be taken in duplicate with the 
sphygmomanometer ( the s ame as  us ed at  c linics) w ith a r esting p eriod of 5  
minutes in between. Our registered research doctor/nurse will take a fasting saliva 
sample as well as a blood sample of 45ml from a vein in your dominant arm. The 
infusion set will be l eft in your arm to lessen the effect of i nserting a needle again 
for blood sampling after exposure to the tw o stressors. A small amount of diluted 
heparin will be left in the infusion set in your arm to prevent clotting.  
Next the c ardiovascular m easurements w ill follow c onsisting of thr ee s eparate 
procedures: 
• The 1 st measurement i nvolves an E CG appar atus, w hich m easures 
heart func tion, with 12  leads, which w ill be placed into pos ition on y our rib 
cage/front part of the body.  
• The 2nd measurements are non-invasive and w ill be done by means of 
the Finometer device which also involves the assessment of heart functioning such 
as pulse (beats per minute), stroke volume (blood volume ejected by the heart per 
beat), c ardiac output ( blood v olume ej ected by  the he art per  minute), total  
peripheral resistance (resistance against the blood flow created by small arteries), 
central resistance (resistance against which the heart has to work while ejecting 
the blood into the aorta) as well as the elasticity of your large arteries (compliance). 
For this procedure a bl ood pressure cuff will be pl aced around your left arm and 
middle finger which will be inflated and stepwise deflated. You will not hav e more 
discomfort t han dur ing a c ommon blood pr essure m easurement. Thi s w ill tak e 
about 5 minutes.  
• The stressor application procedure follows: You will now be exposed to 
a stressor for 1 minute whilst your blood pressure and ECG will still be taken. After 
exposure a saliva and blood sample (45ml) will be taken. After 10 minutes another 
saliva s ample w ill be tak en. Then th e s tressor appl ication pr ocedure w ill be 
repeated with the second stressor.  
• At another station your 3rd measurement includes the assessment of 
pulse wave velocity, i .e. how  fas t your bl ood travels through your arteries. This 
measurement gives us an indication about how stiff your vessel walls are. The 
stiffer your vessel wall is the faster the blood travels from one point of your body to 
another. Th ese p ainless m easurements w ill r equire tw o technicians using bl unt 
probes (tonometer) putting light pressure on th e neck and on the foot to m easure 
the v elocity of the pul se w aves. T his tak es o nly a few  minutes. A n ul trasound 
device will be tak en of y our arteries in the nec k with a bl unt probe to i ndicate the 
intrinsic thickness of your arteries which contributres to high blood pressure.   
The two stressors you will be exposed to for one minute include:  
1. The Colour-Word-Conflict Chart (applied for 1 minute) is written in various 
colours. You must say or select the ink colour rather than the name of the 
colour sp elled out  by  t he w ord. A  sli ding scale w ith monetary incentives 
(maximum of R55.00) will be given if you can complete reading the chart. 
2. The C old Pressor Test  (Foot) (applied for 1 minute): Immersion of  your 
foot up t o the wrist in ice water (4 degrees Celcius). As the cold can make 
you ho ld your br eath yo u m ust qui etly count t o y ourself dur ing c old 
exposure to breath more rythmic.  
 You have reached the end of the sampling phase.  
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 Thank you for your participation! You now will have the opportunity 
to shower and a take away breakfast will be given.  
 Immediate f eedback on  y our H IV/AIDS s tatus, obes ity, bl ood pressure 
and blood glucose/sugar values will be given. HIV/AIDS post-test counselling will 
be arranged if you are tested positive.  
 You are now transported back to your school and after one week you will 
receive your Neethling Brain Instrument and 24-hour blood pressure reports.  
 
Possible Risks 
The m easurements pe rformed i n our  s tudy w ill i nclude onl y n on-invasive 
techniques that ar e no t ex pected to r eveal any  r isks b ut m ight c ause l ittle 
discomfort. The taking of blood samples is an invasive procedure with a minimal 
risk of b leeding. Thus  the pr ocedure m ay c ause onl y a f ew s econds of l ight 
discomfort. All tests will be performed by experienced research nurses of our 
department. There may be additional unforeseen or unknown risks. 
 
Precautions to protect the participant 
The M etabolic U nit fa cility of the  N WU i s ful ly equi pped, and i n c ase of a n 
emergency which c ould not be han dled by  the r egistered nurse, the s upervising 
medical doc tor E mile K otzé w ill be  c ontacted. Dr. K otzé w as noti fied before the 
study commenced that this s tudy w ill be t aking place, and  t hat ther e i s a s light 
possibility that he m ay be c ontacted. Supporting medical treatment care fac ilities 
will be at hand anytime if needed.  
 
Other Treatments Whilst on Study 
It i s important to tel l the  research s taff about any  treatments or  medications you 
may be taking, including non-prescription medications, vitamins or herbal remedies 
during your participation in the study. 
 
Incentives  
1. All teac hers w ill r eceive feedbac k on thei r heal th pr ofile an d i f nec essary 
references will be given to physicians/clinics/hospitals. 
2. Blood pr essure and E CG m onitoring r eport ( normally c osting R 637.60). 
Your benefit of participation is a comprehensive assessment of the cardiovascular 
and m etabolic condition i ncluding i nvestigation of bl ood p ressure, i nflammatory 
status and psychological well-being. These examinations will help us to assess the 
degree of v ascular impairment of t he ar teries and to pr edict your r isk of possible 
cardiovascular ev ents s uch as heart attacks an d s troke. The r esults may as sist 
your doc tor i n dec ision m aking for  fur ther tr eatment or  for  i nstituting  preventive 
measures. Our study will also contribute to the identification of possible factors 
leading to hi gh blood pressure. As 24 hour ambulatory blood pressure monitoring 
is required for the diagnosis of hypertension, medical aids insist on this method of 
diagnosis to  qual ify for  chronic m edication. A dditional te sting c ould al so r eveal 
illnesses of a chronic nature and would serve as a motivation to qualify for chronic 
medication, s uch as  m etabolic s yndrome, a nti-inflammatory and c holesterol-
lowering drugs.  
3. Monetary i ncentive on completion of the colour w ord c onflict chart (± 
R55.00). 
4. Dinner and breakfast (± R24.00). 
5. Neethling B rain Ins trument profiles done by  r egistered us er of the Who le 
Brain (normally costing ±  R350.00). 
6.  Coping skills workshop will be arranged on request. 
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Privacy, Confidentiality and Disclosure of Information 
 
By consenting to participate in this study, you consent to the storage and later 
analysis and testing of your stored blood samples for purposes noted above. Your 
blood samples will be discarded immediately after analysis. All information 
provided by you and the r esults of tests will be treated in the strictest confidence, 
and w ill onl y be us ed for the pur pose of thi s r esearch project. It w ill onl y be 
disclosed w ith y our per mission, ex cept as  r equired by  l aw. The r esults of y our 
medical tests will be labelled only with a code number, and will be stored 
separately from any identifying information. When the r esults are analysed we will 
be l ooking for  di fferences betw een gr oups of peopl e, not at the r esults of  
individuals. No information that could identify any person taking part in the study 
will be revealed when the results are reported. 
 
Participation is Voluntary 
 
Participation in any research project is voluntary. If you do not wish to take part you 
are not obl iged to. If y ou decide to take part and later change your mind, you are 
free to withdraw from the project at any stage.  
Your dec ision w hether to tak e par t or  not to t ake par t, or  to tak e par t and then  
withdraw, will not affect your routine treatment, your relationship with those treating 
you or your relationship with the North-West University. 
Before you make your decision, a member of t he research team will be av ailable 
so that y ou can ask any questions you have about the r esearch project. You can 
ask for any information you want. Sign the Consent Form only after you have had a 
chance to ask your questions and have received satisfactory answers. 
If you decide to withdraw from this project, please notify a member of the research 
team before you withdraw.  
 
Ethical Guidelines 
 
This pr oject w ill be carried out ac cording to Ethical G uidelines of t he Helsinki 
declaration from 2000, w ith addi tional notes  i n 2002. Thi s s tatement has  been  
developed to protect the interests of people who agree to participate in human 
research studies. 
The ethi cal aspects of t his r esearch pr oject ha ve been approved by  t he H uman 
Research Ethics Committee of North-West University Potchefstroom. 
 
Further Information or Any Problems 
 
If y ou require fur ther i nformation or  i f you have any  pr oblems c oncerning thi s 
project, y ou c an contact the pr incipal r esearcher or  the other  researchers 
responsible for this project.  
Dr Leoné Malan (018-299 2438)   
 
Sr. Chrissie Lessing (018-299 2480)    
 
 
 
 
Signature:  
Project Leader:   Dr Leoné Malan 
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PART 2 
 
To the subject signing the consent as in part 3 of this document  
 
You are invited to participate in a research project as described in paragraph 2 of 
Part 1 of this document.  It is important that you read/listen to and understand the 
following general principles, which apply to all participants in our research project: 
 
1. Participation in this project is voluntary. 
2. It is possible that you personally will not derive any benefit from 
participation in t his p roject, alt hough t he know ledge obtained f rom 
the results may be beneficial to other people. 
3. You will b e f ree t o withdraw f rom t he pr oject at  any  stage without 
having to explain the reasons for your withdrawal. However, we would 
like to request that you would rather not withdraw without a thorough 
consideration of  your decision, since it  m ay have an  ef fect on t he 
statistical reliability of the results of the project. 
4. The nat ure of  t he pr oject, possible r isk f actors, f actors w hich may 
cause discomfort, the expected benefits to the subjects and the 
known and the most probable  permanent consequences which may 
follow from your participation in t his project, are discussed in P art 1 
of this document. 
5. We encour age you t o ask quest ions at  any  st age abo ut t he pr oject 
and procedures to the project leader or the personnel, who will readily 
give more information. They will discuss all procedures with you. 
6. We require that you indemnify the University from any liability due to 
detrimental effects of treatment by University staff or students or 
other subjects to yourself or anybody else. We also require indemnity 
from liability of  the University regarding any treatment to yourself or 
another person due to participation in this project, as explained in 
Part 1. Last ly it  is r equired t o abandon an y claim  against  t he 
University regarding t reatment of  yourself or anot her per son due t o 
participation in this project as described in Part 1. 
7. If you are married, it is required that your spouse abandon any claims 
that he/she could have against the University regarding treatment or 
death of yourself due to the project explained in Part 1. 
8. Participation in this project is voluntary. 
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Consent 
 
Title of the  project:   
“THE SABPA STUDY (SYMPATHETIC A CTIVITY AND  AMBULATORY 
BLOOD PRESSURE IN AFRICANS)”. 
 
 
I, the undersigned  …………………………………………………………………
 (full names) 
read/listened to the  i nformation on the pr oject i n P ART 1  and P ART 2 of  thi s 
document and I dec lare that I under stand the i nformation. I had the opp ortunity to 
discuss aspects of the project with the project leader and I declare that I participate 
in the project as a volunteer. I hereby give my consent to be a subject in this 
project. 
 
 
 
 
(Signature of the subject) 
 
 
 
Signed at   ...................................................   on …………………………………2008 
 
Witnesses 
 
1.   ................................................................ 
 
2.  . ............................................................... 
 
Signed at   ...................................................   on …………………………………2008 
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